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1 Zusammenfassung 
Unser Immunsystem schützt uns vor Krankheitserregern wie Mikroorganismen und  
Fremdkörpern, aber auch defekten körpereigenen Zellen, durch ein stark reguliertes Netzwerk 
verschiedener Zelltypen. Funktionsstörungen des Immunsystems können zur Lymphom 
Entwicklung oder Autoimmunkrankheiten wie Multiple Sklerose führen. Das menschliche 
Immunsystem wird in die angeborene und adaptive Immunantwort unterteilt. In beiden 
Systemen besitzt der  NF-κB Signalweg eine wichtige regulatorische Funktion und ist an der 
Kommunikation der Immunantworten untereinander beteiligt. Eine zentrale regulatorische 
Einheit in dem NF-κB Signalweg ist der CBM-Komplex, welcher aus den Proteinen 
CARMA1, BCL-10 und MALT1 besteht. Mutationen dieser Gene können zur Entwicklung 
von Lymphomen oder Autoimmunkrankheiten führen (Hailfinger, 2009; Mc Guire, 2013). 
MALT1 wurde durch die chromosomale Translokation t(11;18)(q21;21) entdeckt. Diese 
Translokation generiert das API2-MALT1 Fusionsprotein, welches die Entwicklung von 
Lymphomen durch konstitutive NF-κB Aktivierung fördert (Akagi, 1999; Morgan, 1999). Die 
proteolytische Aktivität der MALT1 Paracaspase ist an der NF-κB Signalübertragung beteiligt 
und steht im Zusammenhang mit der Lymphom Entwicklung (Ferch, 2009; Hailfinger, 2009). 
Die Inhibierung der proteolytischen Aktivität durch Phenothiazine ist selektiv toxisch für 
ABC-DLBCL Lymphome und besitzt ein immunsuppressives Potential (Nagel, 2012).  
 
Die Hauptziele dieser Arbeit waren, mehr über die Aktivierung von MALT1 zu erfahren, die 
Bildung des CBM-Komplexes zu untersuchen und den Mechanismus der Inhibierung durch 
Phenothiazine zu erklären. Mit Hilfe von strukturbiologischen Methoden wie Elektron-
Mikroskopie wurde die molekulare Anordnung des CBM-Komplexes visualisiert und durch 
Röntgenstrukturanalyse von Proteinkristallen konnte die Phenothiazine Bindungsstelle an 
MALT1 identifiziert werden. Die Bindungskonstanten für verschiedene Phenothiazin- 
Derivate wurden mit der biophysikalischen Methode des Fluoreszenzquenching bestimmt. 
Durch eine gezielte Mutation der allosterischen Bindungsstelle konnte der toxische Effekt von 
Phenothiazin-Derivaten für ABC-DLBCL auf die MALT1 Inhibierung zurückgeführt werden. 
Darüber hinaus stellt die Identifizierung des stereo-selektiven Inhibierungsmechanismus für 
(S)-Mepazine einen bedeutsamen Schritt zu einer effizienteren und MALT1 selektiveren 
Inhibierung dar. 
 
Summary   2 
1 Summary 
Our immune system plays an important role in sensing of environmental conditions to 
protect us against pathogens including microorganisms, foreign substances or defect cells of 
our own body. It is a tightly regulated network of different cell types and disorders of the 
immune system can result in lymphoma development or serious autoimmune diseases like 
multiple sclerosis. The human immune system is divided into the innate and adaptive 
response. The NF-κB pathway has an important regulatory function in both systems and is 
involved in their communication. The CBM-complex is one central regulatory assembly in the 
NF-κB signaling cascade and consists of CARMA1, BCL-10 and MALT1. Mutations in one 
of these genes are connected with the development of lymphoma and autoimmune diseases 
(Hailfinger, 2009; Mc Guire, 2013). Especially, MALT1 was identified by the chromosomal 
translocation t(11;18)(q21;21). This translocation generates the API2-MALT1 fusion protein, 
which supports the development of B-cell lymphoma by constitutive NF-κB activation 
(Akagi, 1999; Morgan, 1999). MALT1 harbors a paracaspase domain, whose proteolytic 
activity is involved in NF-κB signal transduction. Several studies have shown that the 
proteolytic activity of MALT1 is closely connected to the undefined cell growth of lymphoma 
(Ferch, 2009; Hailfinger, 2009). Inhibition of the proteolytic activity by small molecules 
belonging to the class of phenothiazines is selectively toxic for ABC-DLBCL lymphoma and 
has an general immunosuppressive potential (Nagel, 2012).  
 
The main goals of this thesis were to study MALT1 activation, CBM-complex formation and 
mechanism of MALT1 inhibition by phenothiazines. Therefore, structural approaches like 
electron-microscopy were used to determine the molecular assembly of the CBM-complex 
and x-ray crystallography to identify the binding site of phenothiazines on MALT1. 
Biochemical analysis by fluorescence quenching allowed the determination of association 
constants for different phenothiazines. In addition, mutation of the allosteric phenothiazine 
binding site verified the toxic effect of phenothiazines for ABC-DLBCL to origin from 
MALT1 inhibition. Moreover, the identified stereo-selective mechanism of inhibition by 
(S)-mepazine represents a significant step towards more efficient and MALT1 specific 
inhibition.   
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2 Introduction 
The immune system is a concert of cells, sensing environmental conditions to protect us 
against a great variety of pathogens and defect cells of our own body. The human immune 
system consists of the innate and adaptive immune responses (Hoffmann, 1999). The innate 
response is in contrast to the adaptive response less specific, but usually the first reaction to 
pathogens like microorganism. The specificity of the adaptive immune response is based on 
the high receptor variability of antibodies (Agrawal, 1998) and the generation of an 
immunological memory to react against already known pathogens much more efficient. Both 
systems are closely connected and collaborate with each other, but use different types of cells 
and receptors to recognize pathogens (Medzhitov, 2007). Immune cells are derived from 
hematopoietic stem cells (HSCs) in the bone marrow and become multipotent progenitors 
(MPPs), before they differentiate into common myeloid progenitors (CMP) of the innate 
system or common lymphoid progenitors (CLP) of the adaptive immune system (Fig. 2-1) 
(Kondo, 1997; Akashi, 2000).  
 
 
Figure 2-1: Overview of immune progenitor cells. 
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2.1 Innate immune system 
Innate immune cells derived from CMPs differentiate in the bone marrow to granulocytes, 
mast cells or monocytes and subsequently enter the blood stream (Akashi, 2000) (Fig. 2-2). 
Granulocytes harbor big cytosolic granules with immune stimulatory or toxic molecules, 
which are released to the site of infection after activation. Granulocytes are further grouped 
into neutrophils, eosinophils and basophils (Arinobu, 2005) (Fig. 2-2). Neutrophils are mainly 
involved in phagocytosis, while eosinophils are antigen presenting cells with regulatory 
functions. Basophils and mast cells can release additional substances like histamine, resulting 
in increased permeability of surrounding capillaries to push the inflammatory response. 
Monocytes can further differentiate to macrophages and dentric cells (DCs) (Fogg, 2006) 
(Fig. 2-2). These are phagocytic leukocytes and recognize pathogen-associated molecular 
patterns (PAMP) by pattern-recognition receptors (PRR) to discriminate between host and 
pathogen derived molecules (Medzhitov, 2007). Extracellular PRRs like the family of 
Toll-like receptors (TLRs) recognize lipopolysaccharides (LPS) from bacteria or dsRNA from 
viruses, resulting in nuclear factor kappa-light-chain-enhancer of activated B-cells (NF-κB) 
activation and type-I interferon production (Alexopoulou, 2001), further stimulating immune 
cell differentiation and recruitment of additional immune cells. DCs are involved in antigen 
processing and presentation to T-cells of the adaptive system.  
 
Figure 2-2: Overview of innate immune cells. 
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From CLPs derived innate immune cells are defined as innate lymphoid cells (ILCs) and 
include natural killer (NK) cells (Fig 2-2). ILCs have a classic lymphoid cell morphology, but 
unlike adaptive T-, and B-lymphocytes, ILCs lack B-cell receptor (BCR) or T-cell receptor 
(TCR) and do not show antigen specificity (Spits, 2011). ILCs have been further divided into 
three groups based on their cytokine production and transcription factor depending 
development (Spits, 2011).  
Group 1 includes NK cells and produces type-I cytokines like interferon gamma (IFN-γ) and 
tumor necrosis factor (TNF). These cytokines enhance the cellular immune response and 
inflammation. NK cells attack virus infected or tumor cells and have an essential role in 
amplifying inflammatory responses (Vivier, 2011). How NK cells discriminate between 
normal and infected or tumor cells, is generally described by the missing-self-signal 
hypothesis, meaning that sufficient levels of major histocompatibility complex (MHC) class-I 
molecules have to be recognized by inhibitory receptors on NK cells to prohibit attack 
(Karlhofer, 2006). More recently it was shown that several stimulatory receptors on NK cells 
recognize specific signals produced by infected cells or tumor cells (Brown, 2001) and the 
final decision for attack seems to depend on a balanced system between inhibitory and 
stimulatory signals. Signal transduction in NK cells depends among others on the NF-κB 
signaling cascade (Thome, 2004; Gross, 2008). Interestingly, dysregulation of NK cells is 
closely connected to autoimmune diseases (Baxter, 2002).  
Group 2 ILCs are characterized by interleukin (IL) 25 and IL-33 stimulated expression of 
T-helper 2 (Th2) cell associated cytokines, like IL-5 and IL-13 (Klein Wolterink, 2012). Since 
ILC2 cells are able to express MHC class-II molecules, they might be involved in T-cell 
activation by antigen presentation (Wilhelm, 2011), connecting innate and adaptive immunity. 
Moreover, ILC2 cells have been shown to respond on signals produced by T-cells and B-cells, 
providing a feedback mechanism from adaptive to innate immunity (Neill, 2010).  
Group 3 ILCs include lymphoid tissue-inducer (LTi) cells and are able to produce the 
cytokines IL-17 (Cupedo, 2009) and IL-22 (Cella, 2009) like Th17 cells of the adaptive 
immune system. LTi cells participate in lymphoid tissue formation and the maintenance of 
CD4+-memory cells (Withers, 2012). Additionally, group 3 ILCs can produce granulocyte 
macrophage (GM) colony-stimulating factor (CSF) and generally promote immunity (Satoh-
Takayama, 2008) and inflammation (Sonnenberg, 2011).  
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2.2 Adaptive immune system 
Adaptive immune cells are derived from CLPs and separated into T-cells and B-cells, 
according to their defense mechanism. CLPs arriving in the thymus lose their ability to 
become B-cells (Pui, 1999) or NK cells (Michie, 2000) and will differentiate to the T-cell 
lineage, which depends among others on Notch signaling (Radtke, 1999).The interaction of 
the TCR with self-peptide-MHC complexes from antigen-presenting cells (APCs) plays an 
essential role in T-cell development. Initial thymocytes do not express the cluster of 
differentiation (CD) 4 or CD8 surface molecules, defining them as double negative (DN) 
(Fig. 2-3). These thymocytes are subdivided into four classes according to their expression of 
CD25 and CD44 surface molecules (Godfrey, 1993). The DN thymocytes begin to express 
either γδ or αβ chains of the TCR (Robey, 1994). Thymocytes expressing γδ-chain-TCRs 
develop to a small subset of less characterized T-cells. The majority of thymocytes express 
αβ-chain-TCRs and start after αβ-chain rearrangements (Shinkai, 1993) to expose CD4 and 
CD8 surface molecules, defining them as double positive (DP) thymocytes (Robey, 1994). 
These T-cell progenitors migrate through different thymic microenvironments, where they are 
selected according to their functionality and self-tolerance ability by positive and negative 
selection processes.  
Positive selection appears in the cortex by the interaction with self-peptide bound MHC 
molecules of cortical thymic epithelial cells (cTECs). Thereby, the CD4 or CD8 lineage 
commitment depends on the TCR-CD4 interaction with MHC class-II presented molecules 
and on the TCR-CD8 interaction with MHC class-I presented molecules. The “strength of 
signal” model proposes a dependency of signal intensity and duration for correct lineage 
commitment (Matechak, 1996; Ohoka, 1997). Binding of MHC class-II presented molecules 
by the TCR and CD4 tends to produce more frequently a prolonged signal with moderate 
intensity compared to the TCR-CD8 interaction with MHC class-I presented molecules. 
(Veillette, 1989; Wiest, 1993). T-cell progenitors stop either expressing CD4 or CD8 
molecules due to missing activation signals by MHC class-II or MHC class-I presented 
antigens in the different thymic niches. The positive selected T-cells migrate to the medulla, 
undergoing negative selection processing. In contrast to positive selection, high affinity to 
self-peptide bound MHC molecules of bone marrow derived APCs results in apoptosis. T-cell 
progenitors with improper commitment are eliminated during these selection processes. 
Especially, negative selection is essential to prohibit overreaction by self-peptide recognition 
and is connected to autoimmune diseases. 
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Finally selected single positive (SP) CD8+ T-cells leave the thymus as cytotoxic T-cells and 
screen for corresponding antigens on MHC class-I molecules, presented by virus infected 
cells or cancer cells. Activated cytotoxic T-cells produce IFN-ɣ, TNF-α and induce cell death 
by a cytolytic mechanism. In contrast, SP CD4+ T-cells are responsible to activate or regulate 
the immune response and are defined as T-helper cells. Depending on the cytokine micro-
environment, they develop into the specialized subgroups of Th1, Th2, Th17, regulatory 
T-cells (Treg) or follicular helper T-cells (TFH) (Table 2-1).  
First were Th1 cells and Th2 cells identified (Mosmann, 1986). Th1 cell differentiation is 
mainly stimulated by IL-2 and IL-12, produced by activated APCs. Th1 cells express IFN-γ, 
GM-CSF and IL-2 to further stimulate the immune response. Th2 cell differentiation depends 
on IL-4 and activation results in IL-4, IL-5, IL-10 and IL-13 expression. In addition, Th2 cells 
are involved in B-cell activation. The development of Th17 cells depends on IL-6 and 
transforming growth factor-β (TGF-β) (Mangan, 2006; Veldhoen, 2006). Th17 cells are 
IL-17, IL-23 or GM-CSF producing cells and are maintained long-term by IL-21 and IL-23 
(Stritesky, 2008). IL-17 and IL-23 stimulate the immune response (Khader, 2007) and have 
been shown to be implicated in multiple sclerosis (MS) (Langrish, 2005; Veldhoen, 2006), 
inflammatory bowel disease (Duerr, 2006) and rheumatoid arthritis (RA) (Stahl, 2010).  
Treg cells are characterized by TGF-β and forkhead-box-protein P3 (FoxP3) (Chen, 2003; 
Hori, 2003) dependent CD25 expression (Sakaguchi, 2000). These cells express IL-4, IL-10 
or TGF-β and are involved in maintenance of the immunological tolerance by controlling the 
T-cell response. Thus, dysfunction of Treg cells is likely to be implicated in autoimmune 
diseases (Sakaguchi, 1985; Chen, 1994). TFH cells develop after priming inducible T-cell 
co-stimulator ligand (ICOSL) expressing DCs (Fazilleau, 2009b; Choi, 2011). These cells are 
located in T-cell zones, which are in proximity to follicular B-cells and are involved in the 
formation of germinal centers (Fazilleau, 2009a).  
Table 2-1: T-helper cell differentiation and activation effects. 
T-helper cell Differentiation stimulation Activation effects 
Th1 IL-2, IL-12 IFN-γ, GM-CSF, IL-2 expression 
Th2 IL-4 IL-4, IL-5, IL-10, IL-13 expression 
Th17 IL-6, TGF-β / IL-21, IL-23 IL-17, IL-23, GM-CSF expression 
Treg TGF-β, FoxP3 IL-4, IL-10, TGF-β expression 
TFH ICOSL  GC formation 
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The T-cell immune response is divided into the expansion, contraction and memory phases. 
First, antigens presented by APCs in lymphoid tissues and costimulatory signals induce naive 
T-cells to clonally expand and differentiate into effector CD4+ or CD8+ T-cells (Swain, 1990). 
In the contraction phase, the majority of T-cells undergo apoptosis due to the decreasing 
abundance of specific antigens (Badovinac, 2002; Harbertson, 2002). Depending on the CD8+ 
T-cell population size, some T-cells differentiate into a stabilized memory T-cell repertoire to 
provide an effective immune response upon pathogen re-exposure (Murali-Krishna, 1998). 
The differentiation and proliferation of CD4+ memory T-cells differ from CD8+ memory 
T-cells. According to their expression of C-C chemokine receptor type 7 (CCR7), which is 
responsible for locating T-cells to lymph nodes, CD4+ and CD8+ memory T-cells are divided 
into no CCR7 expressing effector memory (TEM) T-cells and CCR7 expressing central 
memory (TCM) T-cells (Sallusto, 1999). TEM are located in non-lymphoid tissues and cannot 
undergo homeostatic turnover. TEM convert to more proliferative TCM and undergo efficient 
homeostatic turnover to store antigen information (Wherry, 2003).  
 
Figure 2-3: Overview of adaptive immune cells. 
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The second defense strategy of the adaptive immune system is represented by the B-cell 
lineage (Fig. 2-3). Initial differentiation from CLPs to pre-B-cells occurs in the bone marrow. 
Hereby, the BCR diversity is based on heavy-chain (HC) rearrangements of the variable (V), 
diversity (D) and joining (J) gene segments, forming the Ig HC (Hardy, 1991). Additional 
binding of surface molecules Igα, Igβ and surrogate immunoglobulin light chains (IgLC) λ5 
and VpreB results in the pre-BCR formation. Pre-BCR signaling together with IL-7 stimulation 
is essential for the survival and proliferation of large pre-B-cells (Corfe, 2012). Highly 
auto-reactive pre-B-cells undergo receptor editing by additional immunoglobulin gene 
rearrangements or die by apoptosis (Nemazee, 2000). Subsequent signaling events lead to 
small resting pre-B-cells and rearrangement of LC genes. Immature B-cells express functional 
BCR in various HC and LC combinations and undergo negative selection in the bone marrow 
to prohibit expansion of auto-reactive clones (Ohashi, 2002). Immature B-cell development is 
continued through several transitional stages in the spleen (Loder, 1999) and further negative 
selection processes (Chung, 2003) prior differentiation to mature follicular or marginal zone 
B-cells (Fig. 2-3).  
Lineage decision and survival of follicular and marginal zone B-cells depends among other 
factors on the BCR signal strength and NF-κB signal transduction by the CBM-complex 
(Ruefli-Brasse, 2003; Xue, 2003), consisting of the caspase-recruitment domain (CARD) 
containing membrane associated guanylate kinase (MAGUK) protein 1 (CARMA1), B-cell 
lymphoma 10 (BCL-10) and mucosa associated lymphoid tissue lymphoma translocation 
protein 1 (MALT1). Marginal B-cells are located in the marginal zone of the spleen and are 
responsible for immune response against bacterial infections (Oliver, 1997). They show 
generally a faster immune response than follicular B-cells and form antibody producing 
plasmablasts in a T-cell independent manner, although some marginal B-cells participate in a 
T-cell dependent manner by presenting antigens and costimulatory signals (Oliver, 1999). 
Follicular B-cells are primarily involved in the T-cell dependent immune response. They are 
circulating through the body and are preferentially located in follicles of secondary lymphoid 
organs close to T-cell zones (Hardy, 1983). Activation occurs by costimulatory signals and 
antigens, diffusing to follicles of secondary lymphoid organs (Pape, 2007) or presented by 
subcapsular sinus (SCS) macrophages (Junt, 2007) and DCs (Wykes, 1998). Initial plasma 
cells differentiated from either marginal or follicular B-cells have a rather short life-time and 
do not produce highly specific antibodies (Smith, 1996). Additional interactions of follicular 
B-cells with TFH-cells and follicular dendritic cells (FDCs) result in formation of germinal 
centers (McHeyzer-Williams, 2001). The architecture of germinal centers is divided into a 
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dark zone and a light zone. The dark zone harbours highly proliferating B-cells, defined as 
centroblasts. In the dark zone occurs the affinity maturation of antibodies by somatic 
hypermutation (SHM) and class-switch recombination (CSR) (Shan, 1990; Jacob, 1991). The 
light zone consists of not proliferating centrocytes. High affinity antibody producing cells are 
selected in the light zone according to their BCR signal strength and differentiate to plasma 
cells or memory B-cells. These cells exit the germinal centers and migrate to the mucosal 
tissues, bone marrow or site of infection (Blink, 2005; Phan, 2006). The interaction between 
CD40 of centrocytes with CD154 of TFH cells is essential for germinal center exit and 
underlies NF-κB mediated transcriptional repression of BCL-6 (Saito, 2007). Binding of 
antibodies to correlating antigens on pathogens initiates macrophage mediated phagocytosis, 
antibody-dependent cell-mediated cytotoxicity (ADCC) by NK cells and neutrophil activation 
(Chan, 1971; Titus, 1987; Anderson, 1990). 
 
2.3 NF-κB pathway in immune cells 
The NF-κB pathway was discovered by the observation of a protein, selectively binding to the 
κ-light-chain enhancer of B-cell tumors extracts (Sen, 1986) and has evolved to one of the 
central signaling pathways, controlling immune cell development, survival, proliferation and 
differentiation by the regulation of cytokine, chemokine, apoptosis regulator and growth 
factor expression (Pahl, 1999). Notable is, the dysregulation of NF-κB signaling is implicated 
in chronic inflammation, lymphoma or autoimmune diseases (Toubi, 2004; Bassères, 2006). 
Transcription factors of the NF-κB family are p50, p52, RelA (p65), c-Rel and RelB. These 
proteins bind as homo-, or hetero-dimers to κB-elements in promoter or enhancer regions to 
activate or repress transcription (Ruben, 1992; Ryseck, 1992).  
Generally, NF-κB signaling has been divided into the canonical and alternative pathway 
according to the activation mechanism (Bonizzi, 2004; Gilmore, 2006). Canonical NF-κB 
signaling is initiated by tumor necrosis factor receptor (TNFR), TLR, BCR or TCR 
stimulation, resulting in formation of the CBM-complex and TNF receptor associated factor 
(TRAF6) assisted recruitment of the inhibitor of NF-kB (IκB) kinase (IKK) complex to the 
membrane (Fig. 2-4) (Hayden, 2004; Landström, 2010). The canonical IKK complex consists 
of the active kinases IKKα, IKKβ and the regulatory IKKγ (NEMO) subunit. Activation 
requires TGF-β activated kinase 1 (TAK1) dependent phosphorylation of the IKKβ kinase. 
Subsequent phosphorylation of NF-κB inhibitor α (IκBα) by IKKβ (Perkins, 2006) leads to 
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K48-ubiquitination of IκBα and following proteasomal degradation of IκBα to release the 
nuclear localization signal (NLS) of RelA, c-Rel, RelB and p50 dimers (Fig. 2-4). 
 
Figure 2-4: Overview of canonical and alternative NF-κB pathway. 
Alternative NF-κB signaling is initiated by B-cell activating factor receptor (BAFFR), TNF 
receptor CD40 or RANK stimulation and results in activation of NF-κB inducing kinase 
(NIK) (Fig. 2-4) (Claudio, 2002; Coope, 2002; Dejardin, 2002). In contrast to the canonical 
pathway, the alternative IKK complex consists of two IKKα subunits and activation depends 
on phosphorylation by NIK (Senftleben, 2001; Xiao, 2004). The processing of p100 to p52 is 
mediated by the active IKK complex and results in nuclear translocation of the p52-RelB 
dimers (Fig. 2-4) (Xiao, 2004) . 
 
2.4 MALT1 paracaspase 
The MALT1 paracaspase was discovered by identification of the chromosomal translocation 
t(11;18)(q21;21) in MALT lymphoma and has been described as binding partner of BCL-10 
(Akagi, 1999; Morgan, 1999). MALT1 consists of a central proteolytic active domain, which 
is homolog to caspases or metacaspases. In contrast to caspases, the paracaspase MALT1 
cleaves substrates after an arginine in P1 position (Uren, 2000; Vercammen, 2007). The active 
site of MALT1 prefers an uncharged residue in P2 position and a hydrophobic residue in P4 
position (Table 2-2) (Hachmann, 2012). The active site of human MALT1 isoform 1 harbors 
the in caspases highly conserved, catalytic active residues, histidine (H415) and cysteine 
(C464) (Uren, 2000). The homolog residues of mouse MALT1 are H423 and C472 (Fig. 2-5). 
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The first identified substrate of MALT1 was BCL-10 (Rebeaud, 2008), but processing of 
BCL-10 is rather involved in T-cell adhesion than NF-κB signaling (Rueda, 2007). First 
evidence for proteolytic dependent NF-κB regulation was shown by MALT1 processing of 
tumor necrosis factor, alpha-induced protein 3 (TNFAIP3 or A20) (Coornaert, 2008). A20 
inhibits NF-κB signaling by removing K63-polyubiquitin chains from TRAF6, IKKɣ and 
MALT1 (Mauro, 2006). MALT1 dependent cleavage of A20 after R439 diminishes the 
deubiquitinase activity of A20 (Düwel, 2009). Afterwards, the substrates cylindromatosis 
(CYLD) (Staal, 2011), RelB (Hailfinger, 2011), Roquin-1 and Regnase-1 have been identified 
(Uehata, 2013; Jeltsch, 2014). Similar to A20, MALT1 dependent processing of CYLD 
inhibits deubiquitination of TRAF2, TRAF6, IKKɣ and TAK1. In contrast to A20, MALT1 
dependent CYLD processing promotes JNK signaling and does not influence NF-κB 
signaling (Staal, 2011). The transcription factor RelB negatively regulates NF-κB signaling 
by inhibiting RelA and c-Rel dependent gene transcription, which is abrogated by MALT1 
processing (Hailfinger, 2011). The ribonucleases Roquin-1 and Regnase-1 are involved in 
mRNA stability and decay. MALT1 dependent cleavage of Roquin-1 results in inactivation of 
ribonuclease activity and achieves efficient translation of NF-κB transcription factor mRNAs, 
essential for Th17 differentiation and IL-17 expression (Jeltsch, 2014).  
Table 2-2: Substrates of MALT1.  
Protein Cleavage site Effects of processing 
A20 GASR439 promotes NF-κB signaling 
BCL-10 LRSR228 involved in T-cell adhesion 
RelB LVSR85 promotes NF-κB signaling 
CYLD FMSR324 promotes JNK signaling 
Regnase-1 LVPR111  promotes NF-κB signaling 
Roquin-1 LIPR510, MVPR579 promotes NF-κB signaling 
 
The proteolytic activity of MALT1 depends on substrate mediated dimerization of the 
paracaspase domain, which is supported by close proximity within the CBM-complex 
(Wiesmann, 2012; Qiao, 2013). C-terminal mono-ubiquitination on K644 stabilizes MALT1 
dimers and enhances the proteolytic activity (Pelzer, 2013). MALT1 plays a key role in T-cell 
development and activation, but the proteolytic activity is not essential for NF-κB activation 
and rather promotes signal transduction. In contrast, the scaffolding function of MALT1 
within the CBM-complex is absolutely necessary for NF-κB mediated gene transcription 
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(Lucas, 2001; Rebeaud, 2008). The scaffolding function of MALT1 relies mostly on the 
additional N-terminal and C-terminal domains. The C-terminal part of MALT1 consists of an 
Ig-like domain (Ig3) and comprises binding sites for TRAF2, TRAF6 and Ubc13 (Sun, 2004; 
Zhou, 2005). TRAF6 binding to MALT1 initiates auto-ubiquitination of TRAF6 and 
subsequent ubiquitination of C-terminal lysine residues of MALT1. This ubiquitination is 
responsible for ubiquitin binding domain (UBDN) mediated recruitment of IKKγ to MALT1 
(Wagner, 2008; Düwel, 2009). The C-terminal region of MALT1 is additionally involved in 
further CBM-complex stabilization by interacting with the coiled-coiled region of CARMA1 
(Che, 2004). The N-terminal part of MALT1 consists of a death domain (DD) followed by 
two immunoglobulin like domains and is mainly involved in BCL-10 binding (Langel, 2008). 
The region between the second Ig-like domain and the paracaspase domain distinguishes the 
two isoforms of MALT1. In contrast to isoform-1, isoform-2 lacks 10 amino acids (309-319), 
which include an additional TRAF6 binding site, represented by the glutamate residues E313 
and E316 (Fig. 2-5) (Noels, 2007). 
 
Figure 2-5: MALT1 domain architecture.  
Moreover, a proteolytic independent role of MALT1 has been proposed for the regulation of 
caspase-8 activity in NF-κB dependent lymphocyte proliferation and activation (Salmena, 
2003; Su, 2005; Kawadler, 2008). The proteolytic inactive caspase homolog cellular FLICE-
like inhibitory protein (cFLIP) participates in regulation of caspase-8 and CD95 stimulated 
apoptosis (Chang, 2002). Caspase-8 mediated processing of cFLIP is involved in TCR 
mediated NF-κB signaling, IL-2 production and reduces the ability to induce apoptosis 
(Micheau, 2002; Misra, 2007). Caspase-8 interacts with the MALT1-BCL-10 complex and is 
recruited with TRAF6 and the IKK complex to lipid-rafts (Su, 2005; Misra, 2007). Hetero-
dimerization of caspase-8 with MALT1 has been proposed to mediate auto-proteolytic 
activation of caspase-8, leading to a specific conformation, which favors cFLIP cleavage, but 
does not allow cleavage of substrates like caspase-3 (Kawadler, 2008). 
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2.5 API2-MALT1 fusion protein 
The chromosomal translocation t(11;18)(q21;21) is frequently observed in MALT lymphoma 
and generates a fusion protein of the C-terminal part from MALT1 and the N-terminal region 
of the inhibitor of apoptosis 2 (API2) (Akagi, 1999; Lucas, 2001). API2 belongs to the family 
of inhibitors of apoptosis (IAP) and consists of three N-terminal baculoviral IAP repeat (BIR) 
domains, central ubiquitin associated (UBA) domain, followed by a CARD domain and 
C-terminal really interesting new gene (Ring) domain. In most lymphoma cases is the BIRC3 
gene, which encodes API2, translocated after N442 to several loci in the MALT1 gene before 
the paracaspase encoding region (Fig. 2-6) (Motegi, 2000; Ye, 2003; Isaacson, 2004).  
 
 
Figure 2-6: API2-MALT1 domain architecture. 
The BIR and UBA domains of API2 are mostly involved in TRAF2 or TRAF6 recruitment 
(Shu, 1996; Lucas, 2007). In addition, the BIR domains of API2 are able to inhibit the activity 
of caspase-3 and caspase-7 (Roy, 1997; Takahashi, 1998). Of particular importance is that 
API2-MALT1 fusion leads to an enhanced proteolytic activity and shows constitutive 
expression of canonical and alternative NF-κB genes, independent of antigen stimulation 
(Lucas, 2001; Zhou, 2005). Mutational studies proposed that constitutive canonical NF-κB 
signaling is due to additional interactions with TRAF2 and TRAF6 by the API2 part 
(Garrison, 2009). Another study proposed BIR1 domain supported oligomerization of 
API2-MALT1 to be responsible for the constitutive NF-κB activation (Zhou, 2005). The 
identification of NF-κB-inducing kinase (NIK) as unique substrate of API2-MALT1 explains 
constitutive activation of alternative NF-κB genes by proteolytic activity dependent formation 
of a less proteasomal degradation prone, but still active kinase fragment (Rosebeck, 2011). 
Most recently, LIM domain and actin binding 1 (LIMα1) has been identified as unique 
substrate of API2-MALT1. LIMα1 is generally known to act as tumor suppressor and 
cleavage by API2-MALT1 results in formation an oncogenic LIM domain only (LMO)-like 
protein fragment (Nie, 2015).  
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2.6 CBM-complex architecture 
The CBM-complex was initially described as Polkadots, which represent big spotted cytosolic 
structures (Rossman, 2006), regulating NF-κB signaling in immune and non-immune cells. 
CBM-complex formation is mediated by protein kinase C (PKC) dependent phosphorylation 
of CARMA proteins (Table 2-3), downstream of immunoreceptor tyrosine-based activation 
motif (ITAM) containing receptors or G-protein coupled receptors (GPCR) (Hara, 2003; 
Matsumoto, 2005; Gross, 2008; Blonska, 2011). CARMA1, also termed CARD11, is specific 
for the spleen, thymus, peripheral blood lymphocytes and functions downstream of antigen 
receptors in T-cells and B-cells or natural-killer group 2, member D (NKG2D) receptor in 
NK-cells (Bertin, 2001; Gaide, 2001; Hara, 2003; Gross, 2008). CARMA3, also known as 
CARD10, functions in immune and non-immune cells downstream of GPCRs and is highly 
expressed in the liver, kidney, heart and brain (McAllister-Lucas, 2001; Wang, 2007). 
CARD9 shows high expression levels in the bone marrow, thymus, spleen (Hsu, 2007) and 
functions downstream of monocyte-activating receptor dectin-1 in macrophages and DNAX-
activation protein 12 (DAP12) associated triggering receptor expressed on myeloid cells 1 
(TREM1) in myeloid and NK-cells (Taylor, 2002; Gross, 2006; Hara, 2007).  
Table 2-3: Overview of CARMA family proteins. 
Protein Alternative name Tissue specificity  Cell types  
CARMA1 CARD11 Spleen, thymus Immune cells 
CARMA3 CARD10 Liver, kidney, heart, brain Immune-, non-immune cells 
CARD9 - Bone marrow, thymus, spleen  Myeloid and NK-cells 
 
These CARMA family members share a similar domain architecture that comprises an 
N-terminal CARD domain followed by a coiled-coil containing linker region. CARMA1 and 
CARMA3 contain an additionally PDZ domain, Src homology (SH) 3 domain and C-terminal 
MAGUK domain (Fig. 2-7) (Bertin, 2001). Upon receptor stimulation, PKC dependent 
phosphorylation of the CARMA1 linker region results in conformational changes from an 
inhibitory to an active state (Matsumoto, 2005; Sommer, 2005). During this thesis a study was 
published that revealed CARMA1 in its active state to function as a nucleator for directional 
BCL-10 polymerization (Qiao, 2013). BCL-10 consists of an N-terminal CARD domain 
followed by an unstructured, serine and threonine rich region (Fig. 2-7). The CARD domain 
of BCL-10 is prone for cooperative polymerization to filaments with a left-handed, single-
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stranded helical symmetry. These filaments are built of intrastrand and interstrand interfaces 
similar to the type II and type I interactions of DD family complexes like in the myddosome 
(Ferrao, 2012; Qiao, 2013). The intrastrand and interstrand interfaces within BCL-10 
filaments are mostly electrostatic, similar to the BCL-10 and CARMA1 interface at the 
filament end (Qiao, 2013). BCL-10 filament growth mediates signal amplification upon a 
certain threshold, sensed by CARMA1 nuclei formation. BCL-10 filament structures enhance 
the proteolytic activity of MALT1 by inducing for activation required proximity of MALT1 
paracaspase domains (Wiesmann, 2012; Qiao, 2013).  
 
Figure 2-7: Overview CBM-complex members.  
 
2.7 CBM-complex dependent NF-κB signaling in T-cells and B-cells 
Canonical NF-κB signaling in adaptive immune cells depends on BCR or TCR signal 
intensity and contact duration with APCs (Gett, 2003; Ruefli-Brasse, 2003). In CD4+ T-cells, 
α-β-chain dimers of the TCR form complexes with CD3 surface molecules (Fig. 2-8). Upon 
TCR stimulation the protein tyrosine kinase (PTK) p56Lck phosphorylates the ITAM of CD3 
molecules (Raab, 1995). Subsequently, the PTK zeta-associated protein-70 (ZAP70) is 
activated by p56Lck dependent phosphorylation and mediates several phosphorylation events 
to recruit phosphatidyl-inositol-3-kinase (PI-3-K) and phospholipase-C-gamma-1 (PLCγ1) 
(Weiss, 1994; Raab, 1995; Yablonski, 1998). PLCγ1 stimulates the hydrolysis of 
phosphatidyl-inositol-2-phosphat (PIP2) to diacylglycerol (DAG) and inositol triphosphate 
(IP3) (Homma, 1992). The generation of IP3 is involved in calcium ion release from 
intracellular storages (Streb, 1983; Berridge, 1993), which participates in signal amplification 
by stimulating the dissociation of the cytoplasmic CD3 domain from the membrane to ensure 
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solvent exposure of tyrosine residues for phosphorylation (Shi, 2012). Additional interactions 
of CD80 and CD86 on APCs with the CD28 receptor on T-cells stimulate PI-3-K mediated 
phosphorylation of the membrane lipid PIP2, resulting in phosphatidyl-inositol-3-phosphat 
(PIP3) formation (Linsley, 1991; Pentcheva-Hoang, 2004; Park, 2009). Auto-phosphorylation 
dependent activation of phosphoinositide-dependent kinase 1 (PDK1) occurs due to PIP3 
assisted membrane recruitment and results in phosphorylation induced activation of PKCθ. 
The activity of PKCθ is additionally enhanced by DAG or calcium ions and initiates CBM-
complex formation by CARMA1 phosphorylation (Fig.2-8) (Lee, 2005; Sommer, 2005).  
 
 
 
Figure 2-8: Model of CBM-complex in NF-κB signaling. 
 
Introduction   18 
A similar mechanism is employed by B-cells, where antigen stimulation induces PTK 
p53/56Lyn to phosphorylate ITAMs in α-β chain dimers of the BCR (Pleiman, 1994). This 
leads to recruitment and activation of SYK, subsequent CD19 assisted PI-3-K activation and 
phospholipase-C-gamma-2 (PLCγ2) phosphorylation (Fig. 2-8). Activation of PLCγ2 is 
promoted by PIP3 mediated Bruton’s tyrosine kinase (Btk) activation and results in the 
generation of IP3 and DAG (Saouaf, 1994; Salim, 1996; Suzuki, 2003). Formation of PIP3 is 
essential for phosphoinositide-dependent kinase-1 (PDK1) recruitment and initiates PKCβ 
dependent phosphorylation of CARMA1 (Lee, 2005; Sommer, 2005).  
Phosphorylation of CARMA1 induces a conformational change that favors the CARD-CARD 
domain interaction with BCL-10 to mediate directional BCL-10 polymerization (Qiao, 2013). 
Finally, constitutive association between MALT1 and BCL-10 results in CBM-complex 
formation (Matsumoto, 2005; Su, 2005; Shinohara, 2007) and interactions of CARMA1 with 
MALT1 further stabilize the CBM-complex (Che, 2004). The following IKK complex 
recruitment to the CBM-complex depends on K63-ubiquitination by TRAF6, ubiquitin 
conjugating enzyme (Ubc13) and Uev1a. The regulatory IKKɣ subunit binds via the UBDN 
domain to the CBM-complex (Sun, 2004; Zhou, 2004; Wagner, 2008). Additional 
K63-ubiquitination of IKKɣ by TRAF6 stimulates recruitment to the plasma membrane, 
where the IKK complex activation is mediated by TAK1 dependent phosphorylation of IKKβ 
(Sun, 2004). The inhibitory IκBα protein is marked for proteasomal degradation by IKKβ 
dependent phosphorylation and subsequent K48-polyubiquitination by the E3 ubiquitin ligase 
SCFIκB. The NLS of NF-κB transcription factors is now accessible for import factor 
facilitated nuclear translocation. 
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2.8 Role of MALT1 in B-cell lymphoma 
Lymphoma derived from marginal zone B-cells are MALT lymphoma among others. MALT 
lymphoma are non-Hodgkin lymphoma occurring in the stomach, lung, bowel and salivary 
gland. MALT lymphoma can arise from gastric inflammation caused by chronic Helicobacter 
pylori infection or autoimmune diseases related effects, frequently observed in patients with 
Sjogren’s syndrome (Isaacson, 2004; Streubel, 2004). Chromosomal translocations of the 
MALT1, BCL-10 and BIRC3 genes have been identified in patients with MALT lymphoma. 
In 15-40% of those patients, API2-MALT1 fusion is caused by the chromosomal translocation 
t(11;18)(q21;q21) (Akagi, 1999). In about 20% of the patients, the chromosomal translocation 
t(1;14)(q32;q21) translocates the MALT1 gene under control of the Ig-heavy-chain enhancer 
and results in MALT1 overexpression (Zhang, 1999; Streubel, 2003). Similarly enhanced 
overexpression of BCL-10 was identified in 5% of the patients, caused by the chromosomal 
translocation t(1;14)(p22;q32).  
Moreover, MALT1 dependent lymphoma can derive from highly proliferative germinal center 
compartments, where B-cells mature to high affinity antibody producing plasma cells. Normal 
germinal center B-cells can develop germinal center B-cell like (GCB) diffuse large B-cell 
lymphoma (DLBCL) and post-germinal center B-cells can give rise to activated B-cell like 
(ABC)-DLBCL (Lenz, 2008b). Several mutations of CARMA1 have been identified in ABC-
DLBCL. These mutations favor the active like conformation and result in antigen independent 
CBM-complex formation, enhanced MALT1 proteolytic activity and constitutive NF-κB 
signaling (Lenz, 2008a; Ferch, 2009; Hailfinger, 2009). Mutations of tyrosine residues located 
in ITAMs of CD79A (Igα) and CD79B (Igβ) have been identified in ABC-DLBCL patients. 
These mutations result in increased BCR expression and inhibit the Lyn kinase activity 
(Davis, 2010). Generally, the Lyn kinase has been shown to play an important role in 
balancing signal transduction and prohibits hyperresponsiveness (Xu, 2005). Depending on 
the stimulus and the B-cell activation state, Lyn kinase either inhibits or promotes NF-κB 
signaling. Signal transduction is achieved by ITAM phosphorylation of Igα and Igβ, 
mediating SYK binding and CD19 phosphorylation supported PI-3-K binding (Xu, 2005). 
The negative regulatory role of Lyn results from ITAM phosphorylation of FcγRIIB or CD22. 
It is worth noting, that mutations in CD79B are responsible for chronic BCR-signaling, 
promoting CBM-complex formation and proteolytic activity of MALT1 (Davis, 2010).  
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2.9 Role of MALT1 in autoimmunity 
Autoimmune diseases are characterized by a defect self-tolerance balance, responsible for the 
development of chronic inflammation and tissue damage. NF-κB signaling regulates immune 
cell development, proliferation, survival and lymphocyte activation. Dysregulation of NF-κB 
signaling is likely to be implicated in various autoimmune diseases. In particular, MALT1 has 
been shown to be involved in rheumatoid arthritis (RA) (Wang, 2014) and multiple sclerosis 
(MS) (Brüstle, 2012). 
Rheumatoid arthritis causes chronic inflammation in joint tissues of feet, knees and hands, 
primarily driven by pro-inflammatory cytokines like IL-1, TNF-α and IL-6. The expression of 
these cytokines depend on NF-κB signaling in activated T-cells and macrophages to stimulate 
the immune response (Campbell, 2000). The function of MALT1 in RA was proposed by 
identification of A20 as negative regulator for pro-inflammatory cytokine expression and 
T-cell activation (Elsby, 2010). A further study identified lower expression levels of A20 and 
MALT1 in RA patients and proposed MALT1 to cause dysregulation of T-cell differentiation 
in RA, similar to multiple sclerosis (MS) (Wang, 2014).  
Multiple sclerosis is caused by an aberrant immune response, leading to tissue damage and 
demyelination of the central nervous system (CNS). The experimental autoimmune 
encephalomyelitis (EAE) is a murine MS model, usually induced by myelin oligodendrocyte 
glycoprotein (MOG) peptide and pertussis toxin (PT), resulting in auto-reactive T-cells, 
infiltrating the CNS similar to MS. Especially, Th1 cells and Th17 cells are proposed to play a 
major role in EAE induction (Jager, 2009). In inflammatory CNS lesions stimulates IL-12 
Th1 cells to activate macrophages by IFN-γ secretion (Merrill, 1992). Th1 differentiation and 
IFN-ɣ expression depends on the NF-κB transcription factors c-Rel and RelB (Kontgen, 1995; 
Corn, 2005). Conversely, further studies revealed that IFN-γ deficient mice are more 
susceptible to EAE and not resistant as expected (Ferber, 1996). Another study identified 
Th17 cells expanded with IL-23 to be responsible for EAE induction (Langrish, 2005). Th17 
differentiation depends on TGF-β, IL-6, IL-21 and IL-23 secretion by APCs (Langrish, 2005; 
Park, 2005; Mangan, 2006; Veldhoen, 2006). Of particular importance is that only IL-23 
driven GM-CSF secretion is indispensable for EAE pathogenesis (El-Behi, 2011). GM-CSF 
expression is either directly mediated by c-Rel activated transcription or indirectly by c-Rel 
dependent Rorɣt expression (Himes, 1996; Codarri, 2011). In addition, c-Rel mediated Foxp3 
expression is involved in Treg differentiation (Zhang, 1999). Interestingly, RelA and RelB are 
essential for ɣδ-T-cells development to restrain Treg responses during EAE by an IL-23 
dependent mechanism (Petermann, 2010; Powolny-Budnicka, 2011).  
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The role of MALT1 in EAE was initially analyzed by MALT1 deficient mice (Brüstle, 2012; 
Mc Guire, 2013). These mice were resistance against EAE induction, similar to previously 
described NF-κB1 (p50), c-Rel and IKKβ deficient mice (Hilliard, 1999; Hilliard, 2002; 
Greve, 2007). The resistance of MALT1 deficient mice is proposed to origin from an 
impaired auto-reactive T-cell immune response. MALT1 deficiency abolishes lymphocyte 
and macrophage infiltration into the spinal cord and results in no detectable pro-inflammatory 
cytokine expression, thus preventing demyelination and axonal damage (Mc Guire, 2013). 
MALT1 deficient mice harbor a reduced amount of Th17 cells with normal expression levels 
of c-Rel and Rorɣt, but show significantly high levels of RelB, primarily located in the 
nucleus. In addition, decreased expression levels of the Th17 effector cytokines IL-17 and 
GM-CSF were identified (Brüstle, 2012). In contrast to the effects on Th17 cells, Th1 
differentiation and their ability for IFN-ɣ and GM-CSF expression is not impaired in MALT1 
deficient mice. Furthermore, MALT1 deficiency has no effect on IL-4 secretion of Th2 cells 
or FoxP3 expression in Treg cells (Brüstle, 2012). Of importance is that Th17 cells show 
generally higher MALT1 expression levels compared to Th1 or Treg cells. In addition, Th cells 
isolated from spinal cord or brain express IFN-γ and IL-17A in contrast to Th cells of MALT1 
deficient mice, expressing either IFN-γ or IL-17A (Brüstle, 2012).  
Further analysis towards the role of MALT1 proteolytic activity was performed by using the 
inhibitor carbobenzoxycarbonyl-val-arg-pro-arg-fluoromethylketone (Z-VRPR-FMK). This 
peptide inhibitor binds covalently to the active site cysteine of MALT1. These experiments 
show a dependency of the proteolytic activity for IL-17A expression by Th17 cells, but no 
effect on Th1 differentiation (Brüstle, 2012). Addressing the proteolytic activity of MALT1, 
the NF-κB and JNK signaling inhibitory proteins A20 and CYLD are completely processed in 
splenic CD4+ T-cells of EAE induced mice, which is mostly abolished in MALT1 deficient 
mice (Mc Guire, 2013). In addition, MALT1 dependent cleavage of Regnase-1 and Roquin-1 
promotes Th17 differentiation (Jeltsch, 2014).  
Most recently, C472A mutant knock-in mice have been characterized in context of EAE 
(Gewies, 2014; Jaworski, 2014). Similar to MALT1 deficient mice, MALT1-C472A mutant 
mice are resistant to EAE induction, represented by reduction of CD4+ T-cells infiltrating the 
CNS and no detectable expression of IFN-γ, IL-17A and GM-CSF by CD4+ T-cells (Fig. 2-9). 
In contrast to MALT1 deficient T-cells, increased expression of IFN-γ by Th1 cells and IL-4 
by Th2 cells have been observed in MALT1 knock-in mice, resulting in lymphocyte 
expansion and accumulation of T-cells in lymph nodes (Jaworski, 2014). Interestingly, no 
effect on IL-17 expression could be identified in MALT1 C472A mice (Jaworski, 2014). 
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Moreover, JNK signaling is not affected in MALT1 C472A mice. In contrast, MALT1 
deficient mice show partial reduced JNK activation. This indicates that the scaffolding 
function of MALT1 is rather responsible for JNK signaling than the proteolytic activity 
(Ruland, 2003; Jaworski, 2014). 
 
 
Figure: 2-9: Influence of MALT1 on the immune response (adapted from Bertossi, 2014). 
 
MALT1 deficient and MALT1 C472A mutant mice show increased RelB levels, proposed to 
be responsible for inhibition of FoxP3 dependent Treg cell differentiation, since significantly 
reduced Treg cell population were identified in the thymus, spleen and lymph nodes (Fig. 2-9) 
(Mc Guire, 2013; Jaworski, 2014). However, no altered FoxP3 mRNA levels could be 
detected and impaired Treg cell differentiation is proposed to depend on MALT1 protease 
activity in a cell-intrinsic manner. MALT1 C472A mutant mice show increased serum levels 
of IgE and IgG1 and are prone to develop spontaneous autoimmune gastritis due to the 
reduced Treg cell population. This is suggested to shift the balance towards autoimmunity 
(Jaworski, 2014). Besides effects in T-cells, MALT1 C472A mutant mice support an essential 
role of MALT1 proteolytic activity for DC and NK cell activation and development of B1 
B-cells or MZ B-cells (Ruefli-Brasse, 2003; Ruland, 2003; Jaworski, 2014).     
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2.10 Inhibitors for MALT1 
The proteolytic activity of MALT1 is inhibited by the inhibitor Z-VRPR-FMK. This peptide 
inhibitor binds covalently to the active site cysteine (C464). Initially, this inhibitor was used 
for the inhibition of metacaspases in plants and could be used for MALT1 inhibition due to 
high homology of the MALT1 active site (Vercammen, 2006). MALT1 inhibition results in 
reduced NF-κΒ activation, IL-2 expression in T-cells (Rebeaud, 2008; Düwel, 2009) and is 
selectively toxic for ABC-DLBCL (Ferch, 2009). Similar to caspases, tetra-peptide binding to 
the active site of MALT1 induces dimerization of the paracaspase domain (Wiesmann, 2012). 
Afterwards, small molecules belonging to the class of phenothiazines were identified by 
establishment of a MALT1 specific cleavage assay, used for high throughput screening (HTS) 
of 18,000 compounds from the ChemBioNet collection (Lisurek, 2010; Nagel, 2012). The 
proteolytic activity of MALT1 was displayed by cleavage induced release of the 7-amido-4-
methylcoumarin (AMC) fluorophore from the substrate Ac-LRSR-AMC, which origins from 
the cleavage site in BCL-10 (Rebeaud, 2008). The identified phenothiazine derivatives 
thioridazine, mepazine and promethazine have a historical clinical use as antipsychotic or 
sedative drugs, suggested to function as dopamine D2 receptor antagonists (Seeman, 1976). In 
particular, MALT1 inhibition by thioridazine or mepazine prevents RelB cleavage, IL-2 
expression in activated T-cells and downregulates NF-κB gene transcription in ABC-DLBCL 
(Nagel, 2012). Moreover, MALT1 inhibition by thioridazine and mepazine reduces the 
growth of ABC-DLBCL due to induction of apoptosis. The toxic effect is specific for 
ABC-DLBCL and does not affect GCB-DLBCL, HBL1 or TM8 cells (Nagel, 2012). Impaired 
T-cell activation by MALT1 inhibition, already suggested an immunosuppressive potential for 
phenothiazines. Recently, mepazine has been shown to attenuate EAE progression without 
affecting Treg development, previously observed in MALT1 deficient mice (Mc Guire, 2014). 
In parallel, MI-2 was identified as a small molecule inhibitor for MALT1 by HTS, using the 
Ac-LRSR-AMC based protease cleavage assay (Fontan, 2012). Similar to phenothiazines 
results MALT1 inhibition by MI-2 in downregulation of NF-κΒ target genes, prevents nuclear 
localization of RelB and is selective toxic for ABC-DLBCL. In contrast to phenothiazines, 
MI-2 contains a reactive chloromethyl amide group and is proposed to bind covalently to the 
active site of MALT1 (Fontan, 2012).  
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2.11 Objectives 
The CBM-complex is one central regulatory assembly in the NF-κB signaling cascade and 
defects in CARMA1, BCL-10 or MALT1 have been shown to be connected with lymphoma 
development and various autoimmune diseases (Akagi, 1999; Mc Guire, 2013). Especially, 
the proteolytic activity of MALT is involved in NF-κB signal transduction and connected to 
the undefined cell growth of lymphoma (Ferch, 2009; Hailfinger, 2009) or development of 
autoimmune diseases (Mc Guire, 2013). Inhibition of the proteolytic activity by small 
molecules belonging to the class of phenothiazines is selectively toxic for ABC-DLBCL 
lymphoma and proposed to have immunosuppressive effects (Nagel, 2012).  
 
The focus of this thesis was to study the mechanism of MALT1 inhibition by phenothiazines. 
Since no crystal structure of MALT1 was known at the beginning of this thesis, x-ray 
crystallography was the method of choice to identify the binding site of these small molecules 
on MALT1. The crystal structure of MALT1 in complex with a phenothiazine will be of 
significant importance to understand the mechanism of MALT1 inhibition. The molecular 
assembly of the CBM-complex was also not known at the beginning of this thesis. Electron 
microscope approaches could give insights into the scaffolding within the CBM-complex and 
further explain effects of CBM-complex formation on the proteolytic activity of MALT1.   
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3 Materials and methods 
3.1 Materials 
Chemicals used in this work were ordered from Sigma-Aldrich (Deisenhofen, DE), Carl Roth 
(Karlsruhe, DE), Merck (Darmstadt, DE) and Enzo Life Sciences (Lausen, DE) or synthesized 
by the chemical institute of the Technische Universität München (TUM) (Munich, DE) and 
Kalexsyn, Inc. (Kalamazoo, US).  
3.1.1 Bacterial strains 
The E.coli XL1 blue strain was used for cloning and the E. coli Rosetta (DE3) strain was used 
for recombinant expression. In particular, the methionine auxotroph B834 (DE3) strain was 
used for expression of seleno-methionine (SeMet) containing protein. 
Table 3-1: Bacterial strains. 
E.coli strain  Genotype Source 
XL1- Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44  relA1 lac [F' proAB lacIqZΔM15 Tn10 (TetR)] 
Stratagene 
(Heidelberg) 
Rosetta (DE3) F- ompT hsdSB (rB- mB-) gal dcm (DE3) pRARE (CamR) 
Novagen 
(USA) 
B834 (DE3) F- ompT hsdSB (rB- mB-) gal dcm met (DE3) pRARE (CamR) 
Novagen 
(USA) 
 
3.1.2 cDNA 
Cloning procedures were performed with the synthetic synthesized complementary 
deoxyribonucleic acid (cDNA) ordered from GeneArt (Thermo Fisher Scientific, DE). The 
DNA sequences were not modified or codon-optimized and used as template DNA. 
Table 3-2: cDNA used for cloning.  
Gene  Species Plasmid Source 
BCL-10 Homo sapiens pCMV6-XL Thermo Fisher Scientific 
BIRC3  Homo sapiens pCMV6-XL Thermo Fisher Scientific 
MALT1 isoform 1a Homo sapiens pCMV6-XL Thermo Fisher Scientific 
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3.1.3 Oligonucleotides 
Oligonucleotides were ordered HPLC purified from Eurofins MWG Operon (Ebersberg, DE) 
or Thermo Fisher Scientific (Ulm, DE).  
Table 3-3: Oligonucleotides used for cloning. 
Name Gene Sequence                                                                              Restriction site 
B3_D25f BIRC3 TACATCATATGGACTTGTCATGTGAACTGTACC Nde- I 
B3_N119r&
M1_D320f 
BIRC3 
MALT1 
CCAAGATTATTTAATTCATCATTTGTTACTGAAGA
AGGAAAAGTAGG 
No 
M1_D320f& 
B3_N119r 
MALT1 
BIRC3 
CCTACTTTTCCTTCTTCAGTAACAAATGATGAATTA
AATAATCTTGG 
No 
M1_T29f MALT1 CCCTTATCAGCCATATGACCCTCAACCGCCTG Nde- I 
M1_L339f MALT1 AAGGAGATATACATATGTTGGCGAAGGACAAG Nde- I 
M1_K128f MALT1 AAGGAGATATACATATGAAGATTACTGTAAACCCA Nde- I 
M1_T29f_sd MALT1 
GTTTAACTTTAAGAAGGAGATATACCATGACCCTC
AACCGCCTG 
No 
sd_M1_T29 MALT1 
CCCTGGCAAGCCATGTCGACTGATAATTTTGTTTA
ACTTTAAGAAGGAGA 
Sal-1 
M1_R719r MALT1 GGTGGTGGTGCTCGAGTCGATGCATGTCTAA Xho-I 
M1_G722r MALT1 GGTGCTCGAGTCCCAAACCTCGATGCATGTC Xho-I 
M1_G722r_s MALT1 
GGTGGTGGTGCTCGAGTCATCCCAAACCTCGATGC
ATGTC 
Stop + 
Xho-I 
M1_E397Af MALT1 CGTAATGCTGTGGATGCGTTTTTACTCCTTTTAG No 
M1_E397Ar MALT1 CTAAAAGGAGTAAAAACGCATCCACAGCATTACG No 
M1_K524Ef MALT1 TAGAAGATAAGGAAATCACTGTGTTACTGG No 
M1_K524Er MALT1 CCAGTAACACAGTGATTTCCTTATCTTCTA No 
B10_M1f BCL-10 CCCTGTTCAGCCATATGGAGCCCACCGCA Nde-1 
B10_E220r BCL-10 AGTCACGATGCGGCCGCTCACTCACTAGAGTTTGC Stop + Not 
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3.1.4 Plasmids 
Table 3-4: Plasmids used for cloning.  
Plasmid  Description Resistance Source 
pet21a C-terminal 6xHis Tag Amp Novagen 
pet28a Cleavable N-terminal 8xHis Tag Kan Novagen 
pGEX6PII Cleavable N-terminal GST Tag Amp GE Healthcare 
pCMV6-XL Cloning vector Amp Thermo Fisher Scientific 
 
3.1.5 Media and antibiotics 
Liquid Lysogeny Broth (LB) media and LB agar plates (1 % NaCl, 1 % bacto-tryptone, 
0.5 %  yeast extract and 1.5 % agar) were prepared according to standard protocols 
(Sambrook, 2001). For expression of SeMet protein, synthetic M9 minimal medium 
supplemented with glucose, vitamins and amino acids with the exception of L-methionine 
(Molecular Dimensions, US) was prepared. Antibiotic stock solutions of ampicillin (amp), 
kanamycin (kan) and chloramphenicol (cam) were prepared with a final concentration of 
250 mM. These stock solutions were sterile filtered prior to use or storage at -20 °C. 
Antibiotic stock solutions were diluted in LB media to a final concentration of 30-50 μg/ml. 
 
3.1.6 Inhibitors for MALT1 
Table 3-5: Inhibitors for MALT1 paracaspase. 
Small molecule Stock concentration Source 
Z-VRPR-FMK 10 mM Enzo Life Sciences 
Hex-LRSR-AOMK 10 mM TU Munich 
Promethazine 50 mM Kalexsyn, Inc 
Mepazine 25 mM Kalexsyn, Inc 
(S)-mepazine 25 mM Kalexsyn, Inc 
(R)-mepazine 25 mM Kalexsyn, Inc 
Thioridazine 50 mM Kalexsyn, Inc 
(S)-thioridazine 50 mM Kalexsyn, Inc 
(R)-thioridazine 50 mM Kalexsyn, Inc 
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3.1.7 Crystallization screens 
Table 3-6: Commercial crystallization screens. 
Name  Company 
Index HTS Hampton Research 
Magic 2  MPI Martinsried  
Procomplex Qiagen 
ClassicI Jena Bioscience 
 
3.2 Molecular biology methods 
Molecular biology methods were performed according to published standard protocols 
(Sambrook, 2001) or indicated separately. Commercial kits and enzymes were used according 
to the manufacturer recommendations. Enzymes used for cloning were purchased from 
Fermentas (St. Leon-Rot, DE) or New England Biolabs (Frankfurt, DE). 
3.2.1 Cloning  
The construct design is based on homology of domain architecture and secondary structure 
prediction by the PSIPRED webserver (Bryson, 2005). Oligonucleotide design and analysis 
was performed by the GeneRunner software. Oligonucleotides contain the desired restriction 
site or hybridizing regions for fusion protein construct generation. DNA fragments were 
amplified by polymerase chain reaction (PCR) using the Phusion® Flash High-Fidelity PCR 
Master Mix (Finnzymes, Espoo, FI). Usually, PCR reactions were performed by a variable 
program (Table 3-7) in a total volume of 20 μl containing 50 ng of template DNA and 
50 pmol of each DNA oligonucleotide. In particular, API2-MALT1 fusion construct 
generation was performed by overlap-PCR (Table 3-7). Amplified DNA fragments were 
purified by mi-PCR Purification Kit (Metabion, DE) and subsequently digested with 
restriction enzymes. DNA fragments were further analyzed by agarose gel electrophoresis and 
purified by mi-Gel Extraction Kit (Metabion, DE). In parallel, plasmids were digested with 
the corresponding restriction enzymes, dephosphorylated by FastAP (Fermentas, DE), 
analyzed by agarose gel-electrophoresis and finally purified by mi-Gel Extraction Kit 
(Metabion, DE). DNA fragments were ligated into the corresponding vector by T4 DNA 
Ligase (Fermentas, DE). Specific clones were selected after transformation in E.coli and 
sequenced by MWG Biotech (Ebersberg, DE).  
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Table 3-7: Program for PCR and overlap PCR. 
Step Temperature [°C] Time [s] Cycles  Cycles overlap PCR 
Initial denaturation   98 120 1 x  
Denaturation 98 15 
30 x 
4x without oligonucleotides 
28x with oligonucleotides 
Annealing 52-57 15 
Elongation 72 (bp/2500)x60 
Final elongation 72 180 1 x  
Stop 4 120 1 x  
Pause 12 oo 1 x  
 
3.2.2 Transformation in E.coli 
Transformations for cloning procedures were performed with E.coli XL-1 Blue and for 
recombinant expression with Rosetta (DE3) (Table 3-1). Cells were made competent 
chemically according to the published protocol (Hanahan, 1983) and frozen in liquid nitrogen. 
Transformations were performed with 150 ng of plasmid from ligation reactions or 10 ng of 
plasmid from a sequenced clone. For transformation, cells were incubated with the plasmid 
for 10 min on ice and subsequently a heat-shock was performed at 42 °C followed by 2 min 
incubation on ice. Afterwards 800 µl of LB were added and cells grew for 1 h at 37 °C before 
plated on LB-agar plates containing the respective antibiotics. Finally, cells were incubated at 
37 °C overnight and selected clones were used for further experiments. 
 
3.2.3 Plasmid expression 
Plasmids were expressed in E.coli Rosetta (DE3) cells (Table 3-1). Therefore, selected clones 
from LB-agar plates were grown overnight at 37 °C in 50-100 ml LB media supplemented 
with the respective antibiotics to a final concentration of 50 μg/ml. Afterwards, 10 ml of these 
pre-cultures were diluted in 3 l LB supplemented with respective antibiotics at similar 
concentrations. Cells were grown at 37 °C until they reached an OD600 of 0.4 and were 
subsequently cooled to 18 °C. The expression was induced at an OD600 of 0.8 by addition of 
0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) and performed overnight. Cells were 
harvested by centrifugation, frozen in liquid nitrogen and stored at -80 °C. Expression of 
SeMet labeled protein was performed in the E.coli B834 (DE3) strain. Therefore, synthetic 
M9 minimal medium (Molecular Dimensions, DE) was used. Finally, 1 ml of 50 mg/ml 
seleno-L-methionine was added to 1 l of media. 
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3.3 Biochemistry methods 
3.3.1 Recombinant protein purification  
The purification strategy depended on the affinity-tag of the construct. Cells containing 
recombinant proteins with C-terminal 6xHis-tag or N-terminal 8xHis-tag were resuspended in 
Lysis Buffer A (Table 3-8), disrupted by sonication at 40 % duty cycle for 15 min and 
centrifuged at 17,000 rpm for 40 min (SLC-6000 Rotor, Sorvall, DE). The supernatant was 
incubated for 20 min with in Buffer A (Table 3-8) equilibrated nickel-nitrilotriacetic acid 
(Ni-NTA) beads (Qiagen, DE) and loaded on 15 ml columns for further washing steps with 
Buffer B (Table 3-8). Afterwards, the proteins were eluted with Buffer C (Table 3-8). Proteins 
containing a C-terminal His-tag were concentrated to 5 ml and centrifuged at 16,000 rpm for 
10 min prior to size-exclusion chromatography or ion-exchange chromatography. Proteins 
containing a cleavable N-terminal 8xHis-tag were dialyzed against 5 l Buffer D (Table 3-8). 
In parallel, cleavage of the His-tag was performed overnight at 12 °C by addition of 1 unit 
PreScission protease per 50 µg of protein (GE Healthcare). Afterwards, the glutathione 
S-transferase (GST) tagged PreScission protease (GE Healthcare, DE) was removed by 
glutathione sepharose affinity chromatography and the flow-through was incubated with pre-
equilibrated Ni-NTA beads (Qiagen, DE) for 20 min at 4 °C. Ni-NTA beads were loaded on 
15 ml column and the flow-through was collected and prepared similarly for size-exclusion 
chromatography or ion-exchange chromatography. 
For purification of proteins containing a GST-tag, cells from 3 l culture were resuspended in 
50 ml Buffer A1 (Table 3-8), disrupted by sonication at a duty cycle of 40 % for 15 min and 
centrifuged at 17,000 rpm for 1 h (SLC-6000 Rotor, Sorvall, DE). The supernatant was sterile 
filtered prior loading on a 5 ml glutathione sepharose column (GE Healthcare) with a flow-
rate of 0.3 ml/min. Several washing steps were performed with a flow rate of 2 ml/min using 
Buffer B1 (Table 3-8). The protein elution was initiated by addition of Buffer C1 (Table 3-8). 
Afterwards, the protein solution was dialyzed against Buffer D1 (Table 3-8). In parallel, 
cleavage of the GST-tag was performed overnight at 12 °C by addition of 1 unit PreScission 
protease per 50 µg of protein (GE Healthcare, DE). The protein solution was loaded with a 
flow rate of 0.3 ml/min on a 5 ml glutathione sepharose column (GE Healthcare, DE). Since 
uncleaved protein and PreScission (GE Healthcare, DE) protease bind to the sepharose 
column, only the flow-through was collected and prepared for size-exclusion chromatography 
by centrifugation at 16,000 rpm for 10 min.  
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Table 3-8: Buffers for cell lysis and affinity chromatography. 
Name Composition 
Buffer A 50 mM Hepes pH 7.5, 300 mM NaCl, 7 mM imidazole, 4 mM ß-mercaptoethanol 
Buffer B 25 mM Hepes pH 7.5, 300 mM NaCl, 21 mM imidazole, 4 mM ß-mercaptoethanol 
Buffer C 25 mM Hepes pH 7.5, 300 mM NaCl, 250 mM imidazole, 4 mM ß-mercaptoethanol 
Buffer D 20 mM Tris pH 7.2, 150 mM NaCl, 2 mM ß-mercaptoethanol  
Buffer A1 50 mM Hepes pH 7.5, 300 mM NaCl, 4 mM ß-mercaptoethanol 
Buffer B1 25 mM Hepes pH 7.5, 300 mM NaCl, 4 mM ß-mercaptoethanol 
Buffer C1 25 mM Hepes pH 7.5, 300 mM NaCl, 20 mM glutathione, 4 mM ß-mercaptoethanol 
Buffer D1 20 mM Tris pH 7.2, 150 mM NaCl, 2 mM ß-mercaptoethanol 
 
Ion-exchange chromatography was performed on an ÄKTA (BASIC) system equipped with a 
5 ml HiTrap Q HP anion exchange column (GE Healthcare, DE) using Buffer E and Buffer F 
(Table 3-9). Peak fractions were analyzed by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and prepared for size-exclusion chromatography. 
Size-exclusion chromatography was performed on an ÄKTA Purifier10 or Purifier100 system 
equipped with a HiLoad 26/60 Superdex 200 pg column or Superose 6 26/60 column 
(GE Healthcare, DE) using Buffer G (Table 3-9). The peak fractions were analyzed by 
SDS-PAGE and selected fractions were pooled, concentrated and frozen in liquid nitrogen. 
Analytical size-exclusion chromatography was performed to determine homogeneity and 
oligomeric state of protein samples. Therefore, an ÄKTA micro or ÄKTA Ettan system 
equipped with a Superdex 200 5/150 GL or Superose 6 PC 3.2/30 (GE Healthcare, DE) and 
Buffer G (Table 3-9) were used. The prepared samples were centrifuged at 16,000 rpm for 
10 min prior to injection and peak fractions were analyzed by SDS-PAGE.    
 
Table 3-9: Buffers for ion-exchange chromatography and size-exclusion chromatography. 
Name Composition 
Buffer E 25 mM Hepes pH 7.5, 100 mM NaCl, 4 mM ß-mercaptoethanol 
Buffer F 25 mM Hepes pH 7.5, 1 M NaCl, 4 mM ß-mercaptoethanol 
Buffer G 25 mM Hepes pH 7.5, 300 mM NaCl, 5 mM DTT 
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3.3.2 Denaturing polyacrylamide gel-electrophoresis (SDS-PAGE) 
Polyacrylamide gel electrophoresis was performed according to the published protocol 
(Laemmli, 1970) using a vertical Mini-PROTEAN 3 system (BioRad). Mostly SDS-gels with 
12 % acrylamide were used. In particular for proteins with a molecular weight below 30 kDa, 
SDS-gels containing 15 % acrylamide were used. Protein samples were prepared with 
4x loading dye (110 mM Tris pH 6.8, 16 % glycerol, 4 % SDS, 5 % ß-mercaptoethanol, 0.6 % 
bromphenol blue) diluted to 1-fold final concentration. Electrophoresis was performed at 
180 V in running buffer (25 mM Tris, 192 mM glycine, 0.1 % SDS). Afterwards, SDS-gels 
were stained in coomassie staining solution (7 % acetic acid, 50 % ethanol, 0.2 % Coomassie 
Brilliant Blue R-250) and destained with deionised water. The relative molecular weight of 
protein bands was determined by comparison with the PAGE RULERTM protein ladder 
(Fermentas, DE). 
 
3.3.3 Dimerization of MALT1  
Dimerization of MALT1 was induced by addition of the covalent binding, substrate like 
peptide inhibitors carbobenzoxycarbonyl-valin-arginine-prolin-arginine-fluoromethyl ketone 
(Z-VRPR-FMK) (Enzo Life Sciences, US) or hexyl-leucine-arginine-serine-arginine-acyloxy-
methyl ketone (hex-LRSR-AOMK) (TUM, DE). The dimerization reaction was performed by 
incubation with 2x excess of inhibitor at 12 °C overnight. The samples were centrifuged at 
16,000 rpm for 10 min prior to size-exclusion chromatography with Buffer G (Table 3-9). The 
peak fractions of monomeric and dimeric MALT1 were collected, analyzed by SDS-PAGE, 
concentrated and used for crystallization. 
 
3.3.4 MALT1 activity assay    
The MALT1 cleavage assay was performed with 20 ng of the MALT1 construct and variable 
concentrations of inhibitor, compound or DMSO. Protein samples were incubated in 384-well 
non-binding microplates and 50 μM of the MALT1 substrate Ac-LRSR-AMC was added. 
After 30 min incubation at 30 °C, the fluorescence of cleaved AMC was measured over 1 h by 
a Synergy 2 Microplate Reader (Biotek, US). The MALT1 protease activity is represented in 
relative fluorescence units. Determination of inhibitory concentration (IC)50 values includes 
data from at least three independent experiments and was performed in PRISM 5 (GraphPad) 
by Nagel D. (AG Krappmann). The Z-VRPR-FMK inhibitor was dissolved in water and the 
compounds were dissolved in DMSO.  
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3.3.5 Fluorescence quenching assay 
The fluorescence spectrometer FluoroMax-P (HORIBA Jobin Yvon, DE) was used to 
determine fluorescence quenching of tryptophan W580 residue in the respective MALT1 
construct. The measurement was performed at an extinction wavelength of 285 nm and 
emission wavelength of 329 nm by 2 μl titration steps of 400 μM, 800 μM, 4 mM, 8 mM 
thioridazine, mepazine or promethazine stock solutions in water against 0.5 μM wt or E397A 
mutant MALT1(L339-R719) in 1.6 ml assay buffer (5 mM Hepes pH=7.0, 300 mM NaCl) 
For promethazine measurements, additional stock solutions (25 mM, 50 mM) were used. The 
tryptophan fluorescence of monomeric and ligand free dimeric MALT1 were recorded with 
increasing amounts of compound. The titration was continued until saturation of quenching 
was observed. The collected data were processed in OriginLab and association constant (KD) 
determination is based on a one binding site curve fitting method.  
 
3.4 Structural biology methods  
3.4.1 Crystallization 
Initial crystallization setups were either performed manually with the Phoenix Crystallization 
Robot (Art Robbins, US) or by the crystallization facility of the MPI Martinsried. Typically, 
350 nl of reservoir and protein solution were used for crystal setups. Crystal plates were 
sealed immediately and stored at 10 °C or 20 °C. The Protein solutions were centrifuged at 
16,000 rpm for 20 min and the reservoir solutions were centrifuged at 3000 rpm for 2 min 
prior to crystallization setups. Generally, a protein concentration of 7 mg/ml was optimal for 
crystallization of API2-MALT1 constructs (Table 3-10).  
The API2(D25-N119)-MALT1(D320-G722) construct with C-terminal His-Tag crystallized 
only in the substrate bound dimeric state. This construct was dimerized with the inhibitor 
Z-VRPR-FMK and crystals could be observed by screening all available crystal screens 
(Table 3-6). Initial crystals were observed in the conditions Hampton Index E11 (0.1 M Hepes 
pH 7.5, 0.2 M magnesium chloride hexahydrate, 22 % poly(acrylic acid sodium salt) 5,100) 
and Magic2 G4 (50 mM Tris pH=7.8, 0.2 NaCl, 22 % PEG 8000). These crystals were further 
refined by hanging-drop vapor diffusion and sitting drop vapor diffusion methods.  
In addition to native protein setups, seleno-methionine containing protein of the His-Tag 
containing construct was used to refine the Magic2 G4 condition (50 mM Tris pH=7.2, 
0.2 NaCl, 18 % PEG 8000).  
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Moreover, in-drop proteolysis was used to obtain high-resolution diffracting crystals. 
Therefore, the protease subtilisin (Sigma-Aldrich, DE) was added to the concentrated protein 
solution with a final concentration of 2 μg/ml and incubated at 20 °C for 30 min prior to 
crystallization setups. In particular, crystals obtained in the Jena Bioscience ClassicI G2 
condition (0.1 M Hepes pH 7.5, 10 % PEG 8000) were used for data collection. These crystals 
were cryo-protected with 25 % glycerol in reservoir solution and frozen in liquid nitrogen. 
Furthermore, crystals of the similar construct with cleaved N-terminal His-Tag were observed 
in the Hampton Index G11 condition (0.1 M Bis-Tris pH 6.5, 0.2 M magnesium chloride 
hexahydrate, 25 % PEG 3350) and were further refined by the hanging drop vapor diffusion 
method. Best crystals were yielded with a protein concentration of 7 mg/ml and the reservoir 
solution (0.1 M Bis-Tris pH 5.5, 50 mM magnesium chloride hexahydrate, 18 % PEG 3350). 
In order to improve diffraction, the decoupling of nucleation and crystal growth method was 
used (Saridakis, 2000). The initial step in crystallization is nuclei formation and occurs if 
protein solution is supersaturated. In contrast, crystal growth is an ordered process and is 
maintained in the metastable zone. In order to separate nucleation and crystal growth, the 
cover-slides of hanging-drop plates were transferred after 14 h from a 18 % PEG 3350 
containing condition to a less precipitant containing condition (14 % PEG 3350). These 
crystals were cryo-protected with 25 % ethylenglycol or 15 % 2,3-butandiol in reservoir 
solution and frozen in liquid nitrogen.  
Table 3-10: Crystallization conditions of API2-MALT1 constructs. 
Protein  Condition Method 
Native protein (7 mg/ml), 
C-terminal 6xHis-tag,  
Z-VRPR-FMK dimerized  
Index E11: 0.1 M Hepes pH 7.5,  
0.2 M magnesium chloride hexahydrate,  
22 % Poly(acrylic acid sodium salt) 5,100 
Hanging drop 
vapor diffusion 
Native protein (7 mg/ml),  
C-terminal 6xHis-tag  
Z-VRPR-FMK dimerized  
Magic2 G4: 50 mM Tris pH=7.8, 0.2 NaCl,  
22 % PEG 8000 
Hanging drop 
vapor diffusion 
SeMet protein (5 mg/ml),  
C-terminal 6xHis-tag,  
Z-VRPR-FMK dimerized  
Magic2 G4: 50 mM Tris pH=7.2, 0.2 NaCl,  
18 % PEG 8000 
Hanging drop 
vapor diffusion 
Native protein (7 mg/ml), 
C-terminal 6xHis-tag,  
Z-VRPR-FMK dimerized  
ClassicI G2:  0.1 M Hepes pH 7.5,  
10 % PEG 8000 
In drop 
proteolysis 
Native protein (7 mg/ml),  
No tag  
Z-VRPR-FMK dimerized  
Index G11: 0.1 M Bis-Tris pH 5.5,  
50 mM magnesium chloride hexahydrate, ,  
18 % PEG 3350 
Decoupling of 
nucleation and 
growth 
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The MALT1(L339-R719) construct crystallized in the ligand-free dimeric and substrate 
bound dimeric state. Initial crystals were observed by using the Hampton Index crystallization 
screen (Table 3-6) with a protein concentration of 8 mg/ml and were further refined to 
optimize crystal growth (Table 3-11).  
For crystallization of Z-VRPR-FMK bound to MALT1(L339-R719), the published condition 
(0.1 M MES pH 6.0, 0.2 M calcium acetate and 2 % benzamidine hypochlorite) (Yu, 2011) 
was used. These crystals were refined by the hanging drop vapor diffusion method. Best 
crystals were yielded by using 1 µl of protein solution at 5 mg/ml and 1 µl of reservoir 
(0.1 M MES pH 5.5, 0.2 M calcium acetate, 10 % benzamidine hypochlorite) at 20 °C. These 
crystals were cryo-protected with 20 % glycerol in reservoir solution and flash frozen in 
liquid nitrogen.  
Crystals of hex-LRSR-AOMK in complex with MALT1(L339-R719) were produced by 
micro-seeding with Z-VRPR-FMK bound crystals. Micro-seeding was performed with the 
Seed Bead kit (Hampton Research, US) by mixing 1 µl of protein solution at 5 mg/ml with 
1 µl of reservoir solution (25 mM MES pH=5.5, 75 mM calcium acetate, 10 % benzamidine 
hypochlorite) and addition of seed-dilutions by using the streak seeding tool (Hampton 
Reasearch, US). The crystal plates were stored at 20 °C. These crystals were cryo-protected 
with 20 % glycerol in reservoir solution and frozen in liquid nitrogen. 
Crystals of ligand-free dimeric MALT1(L339-R719) were observed in the Hampton Index-H8 
condition (0.1 M magnesium formate dihydrate, 15 % PEG 3350), in parallel to publication of 
the crystal structure (Wiesmann, 2012) and were further refined by the hanging drop vapor 
diffusion method. Best crystals were produced by mixing 1 µl of protein solution at 8 mg/ml 
with 1 µl reservoir solution (0.2 M magnesium formate, 13 % PEG 3350) at 20 °C. These 
crystals were cryo-protected with 15 % 2,3-butandiol in reservoir solution and frozen in liquid 
nitrogen.  
The ligand free dimeric MALT1 crystals were soaked with 1.5 mM thioridazine in reservoir 
solution (0.2 M magnesium formate, 13 % PEG 3350) for 14 h to yield crystals of MALT1 in 
complex with thioridazine. Stock solutions of 25 mM thioridazine were freshly prepared with 
deionized water and further diluted in reservoir solution. These crystals were cryo-protected 
with 15 % 2,3-butandiol in reservoir solution and flash frozen in liquid nitrogen.  
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The MALT1(K128-G722) construct crystallized only in the substrate bound state. Initial 
crystals were observed in the A12 condition (100 mM Tris pH=8.0, 1 M NaCl) of the 
Hampton Index crystallization screen. These crystals were further refined by the hanging drop 
vapor diffusion method. Best crystals were yielded by using a protein concentration of 1 
mg/ml. To improve diffraction, methods like seeding and dehydration have been tried. 
Table 3-11: Crystallization conditions of MALT1 constructs. 
Protein  Condition Method 
MALT1(L339-R719) 
Concentration:5 mg/ml 
Z-VRPR-FMK dimerized  
0.1 M MES pH 5.5, 0.2 M calcium acetate, 
10 % benzamidine hypochlorite 
Hanging drop 
vapor diffusion 
MALT1(L339-R719) 
Concentration:5 mg/ml 
Hex-LRSR-AOMK dimerized 
25 mM MES pH=5.5, 75 mM calcium acetate, 
10 % benzamidine hypochlorite 
Hanging drop 
vapor diffusion 
MALT1(L339-R719) 
Concentration:8 mg/ml 
Ligand free, dimeric 
Index H8:  
0.2 M magnesium formate, 13 % PEG 3350 
Hanging drop 
vapor diffusion 
MALT1(L339-R719) 
Thioridazine bound, dimeric  
Index H8:  
0.2 M magnesium formate, 13 % PEG 3350 
Soaking of 
ligand free 
crystals 
MALT1(K128-G722) 
Concentration:1 mg/ml 
Z-VRPR-FMK dimerized 
Index A12:  
100 mM Tris pH=8.0, 1 M NaCl 
Seeding and 
dehydration 
 
3.4.2 Data collection, processing and structure solution 
Data collection of seleno-methionine containing API2(D25-N119)-MALT1(D320-G722) 
crystals was performed at the ID29 beamline (European Synchrotron Radiation Facility, 
Grenoble, FR) at a wavelength of 0.939270 Å, equipped with a PILATUS 6M pixel detector 
(DECTRIS, CH). Data were processed by XDS (Kabsch, 2010). The final structure was 
solved at 3.9 Å by molecular replacement (MR) using PHASER (McCoy, 2007) with the 
published MALT1 structure (pdb entry: 3UOA) as search model (Yu, 2011) and AutoBuster 
(Bricogne, 2011) for refinement. 
Data of the construct with cleaved N-terminal His-Tag were collected at the X06SA beamline 
(Swiss Light Source (SLS), Villigen, CH) at a wavelength of 1.000010 Å, equipped with a 
PILATUS 6M pixel detector (DECTRIS, CH). Data were processed by XDS (Kabsch, 2010) 
and the final structure was solved at 3.6 Å similar to the above described structure solution.  
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Data collection of crystals from subtilisin digested API2(D25-N119)-MALT1(D320-G722) 
was performed at the X06SA beamline (SLS, Villigen, CH) at a wavelength of 1.000000 Å, 
equipped with a PILATUS 6M pixel detector (DECTRIS, CH). Data were processed by XDS 
(Kabsch, 2010) and the structure solved by MR using PHASER (McCoy, 2007) and the 
MALT1 structure (pdb entry: 3V4O) as search model (Wiesmann, 2012). The final structure 
was solved at 3.0 Å by using Phenix (Adams, 2010) for refinement. 
Data collection of crystals containing MALT1(L339-R719) bound to hex-LRSR-AOMK was 
performed at the X06SA beamline (SLS, Villigen, CH) at a wavelength of 1.000010 Å, 
equipped with a PILATUS 6M pixel detector (DECTRIS, CH). Data were processed by XDS 
(Kabsch, 2010) and the structure solved by MR using PHASER (McCoy, 2007) and the 
published MALT1 structure (pdb entry: 3UOA) as search model (Yu, 2011). The final 
structure of MALT1(L339-R719) in complex with hex-LRSR-AOMK was solved at 2.4 Å 
using Phenix (Adams, 2010) for refinement and Coot (Emsley, 2004) for model building.  
 
Table 3-12: Data collection and structure solution.  
Crystal Synchrotron Wavelength Diffraction MR model 
API2(D25-N119)- 
MALT1(D320-G722)  
SeMet protein (Magic2 G4) 
ESRF  
ID29 0.939270 Å Anisotropic,3.9 Å  3UOA 
API2(D25-N119)- 
MALT1(D320-G722)  
No tag (Index G11) 
SLS 
X06SA 1.000010 Å Anisotropic,3.6 Å 3UOA 
API2(D25-N119)- 
MALT1(D320-G722)  
In drop proteolysis (ClassicI G2) 
SLS 
X06SA 1.000000 Å 3.0 Å 3V4O 
MALT1(L339-R719) 
Hex-LRSR-AOMK bound 
SLS 
X06SA 1.000010 Å 2.4 Å 3UOA 
MALT1(L339-R719)  
Thioridazine bound  
ESRF  
ID29 0.972390 Å 2.7 Å 3V55 
MALT1(L339-R719)  
Thioridazine bound  
ESRF  
ID29 1.900000 Å 2.9 Å - 
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Data collection of thioridazine bound MALT1(L339-R719) crystals was performed at the 
ID29 beamline (European Synchrotron Radiation Facility, Grenoble, FR) at a wavelength of 
0.972390 Å, equipped with a PILATUS 6M pixel detector (DECTRIS, CH). Additionally, a 
second data set collected of the same crystal was collected at a wavelength of 1.90 Å. Data 
were processed by XDS (Kabsch, 2010). The structure was solved by MR with PHASER 
(McCoy, 2007), using the paracaspase domain and Ig3 domain of the published ligand free 
MALT1 structure (pdb entry: 3V55) as separate search models (Wiesmann, 2012). The final 
structure of MALT1(L339-R719) bound to thioridazine was solved at 2.7 Å by iterative 
AutoBuster (Bricogne, 2011) refinement and model building steps in Coot (Emsley, 2004). 
All figures used for this thesis were generated in PyMol (Schrödinger, 2015). 
 
3.4.3 Negative staining and electron-microscopy 
All samples were centrifuged 15 min at 16,000 rpm prior to staining with uranyl-acetate. The 
grids were glow-discharged by high voltage supplied for 30 s at 0.3 mbar to render the carbon 
support film hydrophilic. Typically, 3.5 μl of sample were added to the grid, following 45 s of 
incubation and washing with 5 drops of Buffer G (Table 3-9). Subsequently, samples were 
stained with 3.5 μl of uranyl acetate, which was removed immediately by blotting paper. 
Afterwards, samples were stained again with 3.5 μl uranyl acetate and incubated for 15 s. 
Remaining uranyl acetate was removed by blotting paper. Stained particles were visualized by 
the 100 kV “Morgagni” electron microscope. 
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4 Results  
4.1 API2-MALT1 fusion protein 
The chromosomal translocation t(11;18)(q21;q21) generates a fusion protein of the C-terminal 
region from MALT1 and the N-terminal region of API2, frequently observed in MALT 
lymphoma (Akagi, 1999; Lucas, 2001). Generally, expression of API2-MALT1 results in 
constitutive NF-κB activation and supports lymphoma development. In particular, the BIR1 
domain is proposed to participate in the constitutive activation mechanism. Mutational studies 
showed that only the first of the three BIR domains in the API2-MALT1 fusion protein is 
responsible for the constitutive activation mode (Zhou, 2005). Additional TRAF2 interaction 
motifs within the BIR1 domain suggested a crucial role of TRAF2, but mutational studies did 
not approve a TRAF2 dependent mechanism (Varfolomeev, 2007). Another study reproved 
TRAF2 binding to be essential for the constitutive NF-κB activation (Garrison, 2009). In 
concert with the importance of MALT1 oligomerization mediated by BCL-10 (Zhou, 2004) 
and the fact that BIR domains generally tend to oligomerize (Hozak, 2000), BIR1 domain 
induced oligomerization is likely to support MALT1 activation (Zhou, 2005). Moreover, the 
C-terminal Ig3 domain is required for NF-κB activation (Zhou, 2005). Since the mechanism 
of API2-MALT1 activation by the BIR1 domain and function of the Ig3-domain was not 
known, structural studies with recombinant API2-MALT1 fusion protein were performed in 
this thesis. The most promising construct contains the BIR1 domain (D25-N119) from API2 
fused to paracaspase-Ig3 domain part (D320-G722) of MALT1. Both regions were amplified 
separately by PCR using the respective cDNA as template and fused together by overlap-
PCR. Subsequently, DNA fragments were digested by respective restriction enzymes and 
purified prior to ligation into the pet28a vector, containing a cleavable N-terminal 8xHis-Tag 
or into the pet21a vector, containing a C-terminal 6xHis-Tag (Fig. 4-1).     
 
Figure: 4-1: Construct architecture of API2-MALT1.  
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4.1.1 Expression and purification of API2(D25-N119)-MALT1(D320-G722) 
The API2-MALT1-6xHis construct has a calculated molecular weight of 57 kDa. Expression 
was analyzed by the SDS-samples before induction (bI) and before harvesting cells (bH), 
which did not show an upcoming band. Soluble API2-MALT1 protein was bound to the 
Ni-NTA beads and impurities (IP) were partially removed by washing steps prior to protein 
elution (Fig. 4-2 A). Further purification and separation of oligomeric species was performed 
by size-exclusion chromatography. Monomeric API2-MALT1 was eluted at 216 ml and less 
dimeric protein was eluted at 195 ml (Fig. 4-2 B). The Protein fractions were analyzed by 
SDS-PAGE (Fig. 4-2 C) and pooled according to the oligomeric state. Monomeric protein 
was concentrated to 12 mg/ml and dimeric protein to 7 mg/ml. The concentrated samples 
were analyzed by SDS-PAGE and the purity was determined to be suitable for crystallization 
(Fig. 4-2 C). Dimerization of monomeric protein was achieved by incubation with the peptide 
inhibitor Z-VRPR-FMK. Dimeric API2-MALT1 bound to Z-VRPR-FMK was separated from 
the monomeric species by size-exclusion chromatography (Fig. 4-2 D). 
 
Figure: 4-2: Purification of API2-MALT1 (pet21a construct).    
A) SDS-PAGE of Ni-NTA purification. 
B) Size-exclusion chromatogram of purification (S200 26/60). 
C) SDS-PAGE of size-exclusion chromatography fractions and of concentrated samples. 
D) Size-exclusion chromatogram of Z-VRPR-FMK dimerized API2-MALT1 (S200 26/60). 
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Similarly, expression of the 8xHis-API2-MALT1 construct was analyzed by the SDS-samples 
before induction (bI) and before harvesting cells (bH), which did not indicate successful 
expression. The pellet (P) indicated that some protein was insoluble, but enough soluble 
API2-MALT1 protein was bound to Ni-NTA beads and impurities were partially removed by 
washing steps prior to protein elution. The N-terminal His-Tag was cleaved during dialysis 
(D) by PreScission protease, which was afterwards removed by glutathione-sepharose affinity 
chromatography. The uncleaved protein was removed by a second Ni-NTA step and the 
flow-through (nFT) (Fig. 4-3 A) was used for size-exclusion chromatography. Monomeric 
API2-MALT1 protein was eluted at 216 ml (Fig. 4-3 B) and additionally purified by ion-
exchange chromatography using a Q-sepharose column. The samples were analyzed by SDS-
PAGE to determine the purity (Fig. 4-3 C) and pooled accordingly. Monomeric protein was 
concentrated to 12 mg/ml and dimerization of API2-MALT1 was performed by incubation 
with the peptide inhibitor Z-VRPR-FMK. The dimeric species was separated again from the 
monomeric species by size-exclusion chromatography (Fig. 4-3 D).    
 
Figure: 4-3: Purification of API2-MALT1 (pet28a construct).         
A) SDS-PAGE of Ni-NTA purification.   
B) Size-exclusion chromatogram of purification (S200 26/60). 
C) SDS-PAGE of size-exclusion chromatography fractions. 
D) Size-exclusion chromatogram of Z-VRPR-FMK dimerized API2-MALT1 (S200 26/60). 
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4.1.2 Crystallization of API2(D25-N119)-MALT1(D320-G722) 
In order to gain knowledge about API2-MALT1 interfaces and in particular about the role of 
the BIR1 domain, the API2(D25-N119)-MALT1(D320-G722) construct was crystallized. 
Crystals of C-terminal His-Tag containing protein were obtained in the Hampton Index E11 
and Magic2 G4 conditions (see 3.4.1 Crystallization). Best crystals of the refined Hampton 
Index E11 condition (Fig. 4-4 A) diffracted to about 8 Å, but indexing of these images failed. 
Native protein crystals of the Magic2 G4 condition built intergrown crystals, not suitable for 
data collection (Fig. 4-4 B). SeMet protein crystals produced single plate shaped crystals 
(Fig. 4-4 C), but diffracted highly anisotropic to about 3.9 Å. These crystals belong to the 
space group I212121 (Table 4-1). 
 
Figure: 4-4: Crystals of API2-MALT1-6xHis. 
A) Crystals of native API2-MALT1 (Hampton Index E11).   
B) Crystals of native API2-MALT1 (Magic2 G4).    
C) Crystals of SeMet containing API2-MALT1 (Magic2 G4).    
D) Crystals of subtilisin digested API2-MALT1 (Jena Biosience ClassicI G2). 
 
Table 4-1: Data processing, Magic2 G4 condition (SeMet protein). 
Data processing   
Space group I212121  
Cell dimensions   
            a,b,c (Å) 
            α, β, ɣ (°) 
167.9  255.5  251.6  
90.0  90.0  90.0 
 
 
Wavelength (Å) 0.939270  
Resolution (Å) 3.9  
Rsym (%) 19.0 (112.7)  
I / σI 4.19 (1.10)  
Completeness (%) 90.5 (87.6)  
Redundancy 2.2 (2.1)  
* Values in parentheses are for highest-resolution shell. 
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Best crystals of cleaved His-Tag protein were yielded by refining the Hampton Index G11 
condition and using the decoupling of nucleation and growth method (Fig. 4-5 A). Similarly, 
these crystals showed anisotropic diffraction to about 3.5 Å (Fig. 4-5 B) and analysis by 
SDS-PAGE indicated no degradation (Fig. 4-5 C). 
 
Figure: 4-5: Crystals and diffraction pattern of API2-MALT1 (pet28a construct). 
A) Crystal of native API2-MALT1 (Hampton Index G11). 
B) Diffraction image shows anisotropic pattern. 
C) SDS-PAGE of washed API2-MALT1 crystals shows no degradation. 
 
4.1.3 Crystal structure of MALT1(L339-I564) 
First high-resolution diffracting crystals were produced by the in-drop proteolysis method, 
using API2-MALT1-6xHis and subtilisin. Initial crystals (Fig. 4-4 D) diffracted to 3.0 Å and 
belong to the space group P61. Since the crystals lost diffraction power during data collection, 
two data sets were merged, resulting in a completeness of 81.6 % (Table 4-2).  
 
Table 4-2: Data processing and refinement statistics for MALT1 paracaspase domain.   
Data processing   Refinement  
Space group P61  Resolution (Å) 35.92 -3.00 
Cell dimensions   No. reflections 23154 
            a,b,c (Å) 
            α, β, ɣ (°) 
79.1  79.1  181.2  
90.0  90.0  120.0 
 Rwork / Rfree 0. 185/ 0. 246 
 No. atoms  
Wavelength (Å) 1.000000        Protein 3684 
Resolution (Å) 3.0  B-factor (Å²)  
Rsym (%) 9.0 (59.8)        Protein 84.52 
I / σI 5.70 (1.01)  R.m.s deviations  
Completeness (%) 81.6 (82.2)        Bond lengths (Å) 0. 009 
Redundancy  1.1 (1.1)        Bond angles (°) 1.248 
* Values in parentheses are for highest-resolution shell.  R=∑�|𝐹𝑜𝑜𝑜|−|𝐹𝑐𝑐𝑐𝑐|�
∑|𝐹𝑜𝑜𝑜|  (Brünger, 1992) 
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This structure contains only the paracaspase domain and was solved by MR with the in 
parallel published paracaspase domain (pdb: 3V4O) (Wiesmann, 2012). The asymmetric unit 
contains two molecules of the fragment L339 to I564 (Fig. 4-6). 
 
Figure: 4-6: Structure of MALT1 paracaspase domain.  
One monomer is colored light cyan and the other monomer cyan. In both monomers is the substrate 
like inhibitor Z-VRPR-FMK covalently bound to the active site cysteine C464.  
 
4.1.4 Crystal structure of API2(D25-N119)-MALT1(D320-G722) 
Crystals of the cleaved His-Tag API2(D25-N119)-MALT1(D320-G722) protein belong to the 
space group I212121 and diffracted anisotropic to 3.6 Å (Table 4.3). The structure was solved 
by MR using the published MALT1 structure (pdb: 3UOA) as search model (Yu, 2011).  
Table 4-3: Data processing of crystals from Hampton Index G11 condition. 
Data processing   Refinement  
Space group I212121  Resolution (Å) 49.86-3.49 
Cell dimensions   No. reflections 66588 
            a,b,c (Å) 
            α, β, ɣ (°) 
166.0   249.8   255.2 
90.0  90.0  90.0 
 Rwork / Rfree 0.260/ 0.332 
 No. atoms  
Wavelength (Å) 1.000010        Protein 24119 
Resolution (Å) 3.6  B-factor (Å²)  
Rsym (%) 15.8 (176.5)        Protein 136.52 
I / σI 8.42 (1.19)  R.m.s deviations  
Completeness (%) 99.5 (97.1)        Bond lengths (Å) 0. 020 
Redundancy 6.9 (6.3)        Bond angles (°) 1.703 
* Values in parentheses are for highest-resolution shell.  R=∑�|𝐹𝑜𝑜𝑜|−|𝐹𝑐𝑐𝑐𝑐|�
∑|𝐹𝑜𝑜𝑜|  (Brünger, 1992) 
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Unfortunately, the BIR1 domain is not visible in the electron density, although by SDS-PAGE 
analyzed crystals show one band, indicating no degradation (Fig. 4-5 C). The asymmetric unit 
contains 8 molecules of the fragment from L339 to R719. Therefore, building of the final 
structure (Fig. 4-7) was not finished completely. Partially, crystal packing leads to clashes 
between the loops connecting β-sheet GIg3 and FIg3, resulting in minor reorganizations of the 
Ig3 domains.  
 
Figure: 4-7: Crystal structure of API2-MALT1.   
API2-MALT1 crystal structure shows the paracaspase-Ig3 domain of MALT1 with Z-VRPR-FMK 
(orange) bound to the active sites. One monomer of the MALT1 dimer is colored light cyan and the 
other monomer cyan. Indexes for α-helices and β-sheets are according to standard caspase 
nomenclature. 
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4.2 MALT1 activation and allosteric inhibition by phenothiazines 
Crystal structures for the MALT1 paracaspase domain and paracaspase-Ig3 domain were 
published during the thesis (Yu, 2011; Wiesmann, 2012). In parallel, our collaborators 
identified promising small-molecule inhibitors, belonging to the class of phenothiazines 
(Fig. 4-8 A) (Nagel, 2012). Since the mechanism of inhibition was not known, the focus of 
this thesis was to identify the binding-site of these molecules on MALT1. Moreover, binding 
constants for different phenothiazine derivatives could be determined by a fluorescence 
quenching assay. Additionally, our collaborators developed activity based probes for MALT1, 
based on the BCL-10 derived cleavage sequence (LRSR) (Eitelhuber, 2015). In particular, 
additional interactions of the P2 serine residue were of interest. Since all substrate bound 
crystal structures were published with the peptide inhibitor Z-VRPR-FMK, crystallographic 
approaches with the synthesized inhibitor hex-LRSR-AOMK and the published construct 
MALT1(L399-R719) (Yu, 2011; Wiesmann, 2012) (Fig. 4-8 B) were performed. 
 
Figure: 4-8: Phenothiazine derivatives and construct architecture of MALT1(L339-R719). 
A) Chemical structures of phenothiazine derivatives. 
B) Construct design of MALT1(L339-R719). 
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4.2.1 Expression and purification of MALT1(L339-R719) 
Expression of MALT1(L339-R719) was performed in E.coli Rosetta (DE3) cells. Following 
cell lysis, the supernatant was incubated with Ni-NTA beads. Impurities could be partially 
removed during washing steps prior to protein elution (Fig. 4-9 A). Separation of monomeric 
and dimeric species was performed by size-exclusion chromatography. Monomeric MALT1 
was eluted at 232 ml and dimeric MALT1 was eluted at 208 ml (Fig. 4-9 B). The protein 
fractions were analyzed by SDS-PAGE (Fig. 4-9 A) and pooled accordingly. Monomeric 
MALT1 fractions were concentrated to 12 mg/ml and dimeric MALT1 fractions to 7 mg/ml. 
Dimerization of monomeric MALT1 was performed by incubation with the covalent binding 
peptide inhibitors Z-VRPR-FMK or hex-LRSR-AOMK. Inhibitor bound dimeric MALT1 was 
separated from the monomeric species by size-exclusion chromatography (Fig. 4-9 C and D). 
 
Figure: 4-9: Purification of MALT1(L339-R719). 
A) SDS-PAGE of purification and size-exclusion fractions. 
B) Size-exclusion chromatogram of purification (S200 26/60). 
C) Size-exclusion chromatogram of Z-VRPR-FMK dimerized MALT1 (S200 26/60). 
D) Size-exclusion chromatogram of hex-LRSR-AOMK dimerized MALT1 (S200 26/60). 
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4.2.2 Crystallization of MALT1(L339-R719) 
Initially, crystallization of MALT1(L339-R719) was performed with the Z-VRPR-FMK 
dimerized protein, generating single crystals (Fig. 4-10 A). These crystals were further used 
for seeding to produce crystals of MALT1 bound to hex-LRSR-AOMK (Fig. 4-10 B). 
Crystals of ligand free dimeric MALT1 (Fig. 4-10 C) were soaked with thioridazine. 
 
Figure: 4-10: Crystals of MALT1(L339-R719). 
A) Crystal of MALT1 bound to Z-VRPR-FMK. 
B) Crystals of MALT1 bound to hex-LRSR-AOMK. 
C) Crystal of ligand free MALT1 used for thioridazine soaks. 
 
4.2.3 Crystal structure of MALT1(L339-R719) bound to hex-LRSR-AOMK 
Crystals of MALT1 bound to hex-LRSR-AOMK (Fig. 4-10 B) diffracted to 2.4 Å and belong 
to the space group C2 (Table 4-4). These crystals harbor 2 molecules per asymmetric unit. The 
final structure has 734 (96.45 %) residues in the preferred region of the Ramachandran Plot, 
26 (3.42 %) residues are in the allowed region and 1 (0.13 %) residue is defined as outlier. 
Table 4-4: Data processing of MALT1(L339-R719) bound to hex-LRSR-AOMK. 
Data processing      Refinement  
Space group C2  Resolution (Å) 43.94-2.40 
Cell dimensions   No. reflections 27345 
            a,b,c (Å) 
            α, β, ɣ (°) 
178.24, 53.48, 78.74  
90.00, 103.80, 90.00 
 Rwork / Rfree 0.198 / 0.245 
 No. atoms  
Wavelength (Å) 1.000010        Protein 6100 
Resolution (Å) 43.94 - 2.40  B-factors (Å²)  
Rsym (%) 2.8 (38.1)        Protein 73.06 
I / σI 15.06 (1.82)  R.m.s deviations  
Completeness (%) 91.1 (69.2)        Bond lengths (Å)  0.010 
Redundancy 1.72 (1.37)        Bond angles (°) 1.307 
* Values in parentheses are for highest-resolution shell.  R=∑�|𝐹𝑜𝑜𝑜|−|𝐹𝑐𝑐𝑐𝑐|�
∑|𝐹𝑜𝑜𝑜|  (Brünger, 1992) 
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The biological relevant dimeric species was generated by symmetry operations. In both 
monomers is the substrate like inhibitor hex-LRSR-AOMK covalently bound to the active site 
cysteine C464 (Fig. 4-11 A). Electrostatic surface representation shows the positively charged 
S1 and S3 pocket, coordinating the P1 and P3 arginine. In contrast, the S4 pocket is mostly 
hydrophobic (Fig. 4-11 B). Substrate binding induced reorganization of the active site Loops 
(L1-L4), in particular of the L4 loop, is connected to the dimerization interface of β-sheet 8 
(Fig. 4-11 C). Moreover, the L4-loop and β-sheet 8 represent a direct connection to the 
linking helix and Ig3 domain.  
 
Figure: 4-11: Crystal structure of MALT1(L339-R719) bound to hex-LRSR-AOMK. 
A) Overview of MALT bound to hex-LRSR-AOMK crystal structure. One monomer is colored blue 
and the other monomer in cyan. In both monomers is the inhibitor hex-LRSR-AOMK illustrated 
in yellow and covalently bound to the active site cysteine C464. Indexes for α-helices and 
β-sheets are according to standard caspase nomenclature. 
B) Electrostatics surface representation of active site pocket (red -6 kT to blue +6 kT). 
C) Connection from active site to Ig3 domain is highlighted in orange. 
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Besides the already published dimerization mutant R551E, which is located in β-sheet 8 and 
abolishes MALT1 protease activity (Wiesmann, 2012), lysine 524 (K524) is located next to 
α-helix F and expected to play an important role in dimerization. The crystal structure of 
MALT1 in complex with hex-LRSR-AOMK shows K524 to interact with aspartate (D330’) 
and glutamate (E534’) of α-helix F’ from the opposing monomer (Fig. 4-12 A). Furthermore, 
E534 is stabilized in this position by electrostatic interactions with K557, which is located in 
the loop emerging from β-sheet 8 and connects the paracaspase domain with the Ig3 domain 
(Fig. 4-12 A). Mutation of K524 to glutamate was expected to disrupt the interaction with 
D530 and E534, permitting structural reorganization and dimerization. To further verify the 
effect of K524E mutation in solution, dimerization by incubation with the substrate like 
peptide inhibitor Z-VRPR-FMK was analyzed by analytical size-exclusion chromatography, 
showing no formation of dimeric species for K524E mutant MALT1 (Fig. 4-12 B). Thus, the 
stabilizing interaction of K524 is required for dimerization of MALT1.    
 
Figure: 4-12: Dimerization interface and K524E mutation of MALT1. 
A) Detailed view of MALT1 dimerization interface with interacting residues as stick model. One 
monomer is colored blue and the other monomer cyan. The connection between the active site and 
Ig3 domain is highlighted in orange. 
B) Overlay of analytical size-exclusion chromatograms shows no dimeric species for K524E mutant 
MALT1 after incubation with the covalent binding peptide inhibitor Z-VRPR-FMK.  
 
Biochemical studies revealed by using a positional-scanning substrate combinatorial library 
that residues P2 and P3 are less selective with the greatest tolerance in P3, while in position 
P4 leucine or phenylalanine are clearly preferred residues (Hachmann, 2012). These data fit 
well with the observation that the LRSR bound crystal structure possess a well ordered L4 
substrate binding loop and the non-polar P4 leucine fits perfectly in the hydrophobic S4 
pocket composed of the residues F499, I501, I510 and L541 (Fig. 4-13 A). In contrast, the P3 
arginine is mainly coordinated by electrostatic interactions with Q502 and E500. The 
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backbone of the peptide inhibitor shows additional interactions to E500 and A498. The P2 
serine of the inhibitor does not show any additional interactions. The P1 arginine is highly 
coordinated by electrostatic interactions with D365 and D462. The L2 loop contains the active 
site cysteine C464, which forms a covalent bond to the inhibitor peptide upon reacting with 
the AOMK molecule. Thereby, the caspase typical active site histidine (H415) stabilizes the 
negatively charged tetrahedral intermediate with the δN atom. Additionally, the backbone 
oxygen of proline (P357) is responsible to keep H415 in place (Fig.4-13 B). 
 
Figure: 4-13: Detailed view of active site containing hex-LRSR-AOMK. 
A) Top view of the MALT1 active site with hex-LRSR-AOMK represented in standard orientation, 
hydrophobic S4 pocket building residues are represented as stick model. 
B) Illustration of electrostatic inhibitor coordination. Interacting residues are represented as stick 
model and the peptide inhibitor hex-LRSR-AOMK is presented in standard orientation. 
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4.2.4 Crystal structure of MALT1(L339-R719) in complex with thioridazine 
Diffraction of thioridazine soaked crystals (Fig. 4-10 C) depended extremely on thioridazine 
concentration and incubation time. Either crystals lost diffraction power or did not contain the 
inhibitor. In contrast to native crystals, which diffracted to about 1.9 Å, only one thioridazine 
containing crystal diffracted to 2.7 Å and belongs to the space group C2 (Table 4-5). This 
crystal harbors one molecule per asymmetric unit. In addition to the native dataset at 
λ = 0.972390 Å, a second dataset at λ = 1.900000 Å was collected to visualize the anomalous 
sulfur signal of thioridazine (Table 4-5). The final structure has 328 (95.35 %) residues in the 
preferred region of the Ramachandran Plot, 15 (4.36 %) residues fall in the allowed region 
and 1 (0.29 %) residue is defined as outlier. The biological relevant dimeric species was 
generated by crystallographic operations (Fig. 4-14). Most important, the structure reveals 
that compounds of this tri-cyclic inhibitor class bind in a pocket located on the opposite site 
relative to the caspase active site, in the interface between the caspase domain and the Ig3 
domain connecting α-helix Ig3 of MALT1. The active site and in particular the L2 loop are 
mostly unstructured, similar to the ligand free structure (Fig. 4-14) (Wiesmann, 2012) 
 
Table 4-5: Data processing of MALT1(L339-R719) in complex with thioridazine. 
Data collection   Refinement  
 native data              anomalous data   
Space group C2 C2 Resolution (Å) 41.09 - 2.70 
Cell dimensions   No. reflections 10386 
            a,b,c (Å) 
            α, β, ɣ (°) 
94.8, 70.6, 57.5    
90.0, 93.6, 90.0 
94.9, 70.7, 57.5  
90.0, 93.6, 90.0       
Rwork / Rfree 0.200/ 0.249 
No. atoms  
Wavelength (Å) 0.972390 1.900000    Protein 2803 
Resolution (Å) 47.32 - 2.70 47.34 - 2.84 B-factor (Å²)  
Rsym (%) 3.8 (61.2) 5.4 (51.5)    Protein 86.51 
I / σI 17.69 (1.75) 11.79 (1.80) R.m.s deviations  
Completeness (%) 98.6 (97.8) 97.4 (94.7)    Bond lengths (Å) 0.013 
Redundancy 3.08 (3.11) 2.83(2.74)    Bond angles (°) 1.26 
* Values in parentheses are for highest-resolution shell. R=∑�|𝐹𝑜𝑜𝑜|−|𝐹𝑐𝑐𝑐𝑐|�
∑|𝐹𝑜𝑜𝑜|  (Brünger, 1992) 
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Figure: 4-14: Crystal structure of MALT1 in complex with thioridazine. 
Crystal structure shows the MALT1 dimer with one monomer colored gold and the other 
monomer colored sand. The small molecule inhibitor thioridazine binds in the interface 
between the paracaspase and Ig3 domain and is represented as magenta stick model. Indexes 
for α-helices and β-sheets are according to standard caspase nomenclature. 
 
The anomalous difference density map of sulfur atoms was used to determine the orientation 
of the 2-methylsulfanylphenothiazine ring. In detail, the tri-cyclic ring system of thioridazine 
is bound in a hydrophobic pocket composed of residues A394, F398, L401 in α-helix C and 
L346, V344 and V381 in β-sheets 1 and 2, respectively (Fig. 4-15 A). Additional to this 
hydrophobic pocket, residue E397 forms a prominent hydrogen bond to the nitrogen of the 
N-methylpiperidine group of thioridazine (Fig. 4-15 A). Moreover, a detailed inspection of 
the refined 2Fo - Fc electron density map suggests only the S-enantiomer of thioridazine to be 
bound in the crystal structure. Electrostatic surface representation of the binding site 
illustrates perfect fitting of thioridazine into the allosteric binding pocket (Fig. 4-15 B). 
 
 
Figure: 4-15: Detailed view of thioridazine binding site. 
A) A detailed view of the thioridazine binding site shows the compound as magenta stick model 
surrounded by the in blue illustrated refined 2Fo – Fc electron density map (contoured at 1 σ). The 
anomalous difference density map (contoured at 2,2 σ) is highlighted in yellow. 
B) Surface representation of thioridazine binding pocket (red -6 kT to blue +6 kT). 
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4.2.5 MALT1 fluorescence quenching assay  
In order to verify the mechanism of inhibition in solution and the binding site to be universal 
for phenothiazines, a tryptophan fluorescence quenching assay was developed. Upon binding, 
the side chain of residue tryptophan 580 (W580) on α-helix 1Ig3 is flipped out of the 
hydrophobic groove into a solvent exposed environment (Fig. 4-16 A). For this assay, 
advantage was taken from the fact, that W580 is the only tryptophan residue in the 
MALT1(L339-R719) construct and in close proximity to the tri-cyclic compound. As 
expected by the binding mode of thioridazine observed in the crystal structure, the intrinsic 
fluorescence of W580 is quenched by the presence of the compound. The high magnitude of 
quenching suggests that in addition to the solvent quenching effect, a process of energy 
transfer might occur by the close proximity of the drug to the tryptophan residue. Mutation of 
E397 to alanine prevents the main interaction between MALT1 and thioridazine and verifies 
the proposed binding mechanism. 
 
Figure: 4-16: Fluorescence quenching assay of monomeric MALT1. 
A) Tryptophan flipping mediated by thioridazine binding. 
B) Fluorescence quenching assay of monomeric MALT1 with thioridazine. 
C) Fluorescence quenching assay of monomeric MALT1 with mepazine.  
D) Fluorescence quenching assay of monomeric MALT1 with promethazine. 
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Indeed, the E397A mutation has significant effects on association constants of all analyzed 
compounds (Table 4-6). The determined association constants for thioridazine are 22.6 µM 
using wt MALT1 and 57.3 µM using E397A mutant MALT1 (Fig. 4-16 B). The association 
constants for mepazine are 16.0 µM for wt MALT1 and 78.9 µM for E397A mutant MALT1 
(Fig. 4-16 C). Importantly, the fluorescence quenching assay verifies the binding site to be 
universal for several phenothiazine derivatives and shows mepazine to have the greatest 
inhibitory potential of all analyzed compounds. Mepazine has similar to thioridazine a strong 
dependency on the interaction between E397 and the N-methylpiperidine group. In contrast, 
promethazine is lacking the N-methylpiperidine group and has less inhibitory potential, 
represented by association constants of 103.2 µM for wt MALT1 and 119.0 µM for E397A 
mutant MALT1 (Fig. 4-16 D). The oligomeric state of MALT1 has no influence on the 
inhibitory potential, since association constants for monomeric and dimeric MALT1 are in 
comparable range, represented by association constants for thioridazine of 22.4 µM for 
monomeric MALT1 and 20.9 µM for dimeric MALT1 (Fig. 4-17 A). Similarly, comparable 
association constants for mepazine of 16.1 µM using monomeric MALT1 and 19.8 µM using 
dimeric MALT1 were determined (Fig. 4-17 C).  
 
Figure: 4-17: Fluorescence quenching assay. 
A) Fluorescence quenching assay of monomeric and dimeric MALT1 with thioridazine. 
B) Stern-Volmer plot of monomeric and dimeric MALT1 with thioridazine. 
C) Fluorescence quenching assay of monomeric and dimeric MALT1 with mepazine. 
D) Stern-Volmer plot of monomeric and dimeric MALT1 with mepazine. 
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Table 4-6: Association constants for phenothiazine derivatives. 
Small molecule wt MALT1, KD [µM] E397A  MALT1, KD [µM] 
Promethazine 103.2 119.0 
Mepazine 16.0 78.9 
(S)-mepazine 8.5  - 
(R)-mepazine 29.9 - 
Thioridazine 22.6 57.3 
(S)-thioridazine 21.3 - 
(R)-thioridazine 23.0  - 
 
The fluorescence data were analyzed according to the Stern-Volmer law (Eftink, 1981) 
(Fig. 4-17 B and D), pointing to a combination of dynamic and static fluorescence quenching 
effects. Most importantly, the refined 2Fo – Fc electron density map around thioridazine 
suggests preferentially binding of (S)-thioridazine (Fig. 4-15 A). Regarding the inhibitory 
potential of thioridazine enantiomers, no significant effect could be observed by fluorescence 
quenching, represented by comparable association constants of 23.0 µM for (R)-thioridazine 
and 21.3 µM for (S)-thioridazine (Fig. 4-18 A). Surprisingly, the fluorescence quenching 
assay shows significant different association constants for the mepazine enantiomers. In 
particular, preferential binding of (S)-mepazine was observed, represented by associations 
constant of 8.5 µM for (S)-mepazine and 29.9 µM for (R)-mepazine (Fig. 4-18 B).  
 
 
Figure: 4-18: Fluorescence quenching assay of thioridazine and mepazine enantiomers. 
A) Fluorescence quenching assay of monomeric MALT1 with thioridazine enantiomers. 
B) Fluorescence quenching assay of monomeric MALT1 with mepazine enantiomers. 
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4.3 Molecular assembly of MALT1 and BCL-10 
In order to gain insights in the interplay between the different domains of MALT1, death 
domain truncated MALT1(K128-G722) (Fig. 4-19 A) was recombinant expressed and used 
for crystallization setups. In addition, MALT1(T29-G722) (Fig. 4-19 B) in complex with 
BCL-10(M1-E220) (Fig. 4-19 C) was either co-expressed or expressed by a polycistronic 
expression system and analyzed by EM to visualize the molecular assembly. 
 
Figure: 4-19: MALT1 and BCL-10 construct architecture. 
A) Construct design of MALT1(K128-G722).    
B) Construct design of MALT1(T29-G722).    
C) Construct design of BCL-10(M1-E220).    
 
4.3.1 Expression, purification and crystallization of MALT1(K128-G722) 
The MALT1(K128-G722) construct was cloned into the pet28a vector and expression was 
performed in E.coli Rosetta (DE3) cells. Soluble recombinant protein was bound to Ni-NTA 
beads by its N-terminal His-Tag. Some impurities were removed during the washing step (W). 
The proteins were eluted and cleavage of the N-terminal His-Tag was performed during 
dialysis. The cleavage efficiency was visualized by the SDS-samples before dialysis (bD) and 
after dialysis (aD). The PreScission protease was removed by an additional affinity 
chromatography step using a glutathione-sepharose column (-PP). Afterwards, cleaved protein 
could be separated from uncleaved protein by a second Ni-NTA affinity chromatography 
(Fig. 4-20 A). The flow-through (nFT) was used for further purification by size-exclusion 
chromatography. MALT1 was eluted at 214 ml (Fig. 4-20 B), the respective protein fractions 
were analyzed by SDS-PAGE, showing the final purity (Fig. 4-20 C). Dimerization of 
MALT1 was performed by incubation with the substrate like peptide inhibitor Z-VRPR-FMK 
and subsequent size-exclusion chromatography. Substrate bound dimeric MALT1 was eluted 
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at 175 ml (Fig. 4-20 D), the respective fractions were pooled, concentrated to 4 mg/ml and 
used for crystallization (Fig. 4-20 E). These crystals diffracted to 20 Å, but could not be 
improved by refinement or different crystallization methods like seeding and dehydration.   
 
Figure: 4-20: Purification and crystallization of MALT1(K128-G722). 
A) SDS-PAGE of purification. 
B) Size-exclusion chromatogram (S200 26/60). 
C) SDS-PAGE of size-exclusion fractions. 
D) Size-exclusion chromatogram of Z-VRPR-FMK dimerized MALT1 (Superose-6 26/60). 
E) Crystals of MALT1(K128-G722). 
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4.3.2 Expression, purification and structural analysis of BCL-10 and MALT1 
Initially, MALT1(T29-G722) was cloned into the pet28a vector and BCL-10(M1-E220) was 
cloned into the pGEX6PII vector. Co-expression was performed in E.coli Rosetta (DE3) cells. 
After cell lysis, the SDS-sample of the pellet (P) indicated that proteins were partially 
insoluble. However, soluble recombinant BCL-10 was bound to the glutathione-sepharose 
column and was eluted together with MALT1. Cleavage of the N-terminal GST-Tag of 
BCL-10 and N-terminal His-Tag of MALT1 was performed by addition of PreScission 
protease prior to dialysis. The cleavage efficiency was visualized by SDS-PAGE of the 
samples before dialysis (bD) and after dialysis (aD), showing complete cleavage of both tags 
(Fig. 4-21 A). The PreScission protease and cleaved GST were removed by an additional 
glutathione-sepharose affinity chromatography step. During concentration of the flow-through 
(FT2), aggregation was observed. The aggregates were separated from the supernatant by 
centrifugation and the supernatant was used for initial negative staining with uranyl-acetate.  
 
Figure: 4-21: Purification of BCL-10 and MALT1. 
A) SDS-PAGE of first GST purification.    
B) SDS-PAGE of second GST purification.  
C) Size-exclusion chromatogram of GST containing complex (Sepharose-6 26/60). 
D) SDS-PAGE of size-exclusion fractions from GST containing complex.    
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Surprisingly, filamentous structures with cross interactions could be observed (Fig. 4-22 A). 
Afterwards, similar expression and initial glutathione-sepharose affinity chromatography were 
performed and visualized by SDS-PAGE (Fig. 4-21 B). Since the complex of GST-BCL10 
and MALT1 was partially stable, the eluted complex was further purified by size-exclusion 
chromatography. Aggregates of GST-BCL-10 and MALT1 were eluted at the exclusion 
volume of 42 ml and some soluble complex was eluted at 55 ml (Fig. 4-21 C). Size-exclusion 
fractions indicated auto-proteolytic processing of MALT1 (Fig. 4-21 D). The soluble complex 
was used for negative staining and EM analysis showed sphere shaped particles with an 
approximate diameter of 0.05 µm (Fig. 4-22 B). 
 
Figure: 4-22: EM analysis of BCL-10-MALT1 complex. 
A) Negative stained BCL-10-MALT1 complex shows filamentous structures (110kx). 
B) Negative stained GST-BCL-10-MALT1 complex shows sphere shaped particles (110kx).  
 
Due to relatively low expression, MALT1(T29-G722) was cloned into the BCL-10 containing 
pGEX6PII vector. Polycistronic expression was achieved by addition of an N-terminal Shine-
Dalgarno (SD) sequence to the MALT1 construct. The expression was analyzed by the 
SDS-samples before induction (bI) and before harvesting cells (bH), indicating successful 
expression by an upcoming band. Following cell lysis, purification was performed by 
glutathione-sepharose affinity chromatography. One half of the protein solution was used for 
GST-tag cleavage by PreScission protease. The cleavage efficiency was visualized by the 
SDS-samples before dialysis (bD) and after dialysis (aD). The PreScission protease and GST 
were completely removed by an additional glutathione-sepharose affinity step (Fig. 4-23 A). 
The collected flow-through (FT2) was used for size-exclusion chromatography (Fig. 4-23 B) 
and subsequent negative staining. The EM analysis revealed again filamentous structures with 
cross interactions (Fig. 4-23 C). The other half of protein solution was not cleaved by 
PreScission protease and directly analyzed by size-exclusion chromatography. Similar to 
previous results, aggregates were eluted at 42 ml and the soluble complex was eluted at 58 ml 
(Fig. 4-23 D). The corresponding fractions were visualized by SDS-PAGE, indicating 
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MALT1 self-cleavage products (Fig. 4-23 E). The soluble complex was used for negative 
staining and further analysis by EM showed sphere shaped particles with an approximate 
diameter of 0.05 µm (Fig. 4-23 F).  
 
Figure: 4-23: Purification and EM analysis of polycistronic expressed BCL-10-MALT1. 
A) SDS-PAGE of Ni-NTA purification.    
B) Size-exclusion chromatogram of GST cleaved BCL-10-MALT1 complex (S200 26/60). 
C) Negative stained BCL-10-MALT1 complex shows filamentous structures (56kx). 
D) Size-exclusion chromatogram of GST-BCL-10-MALT1 complex (Sepharose-6 26/60). 
E) SDS-PAGE of size-exclusion fractions from GST-BCL-10-MALT1 complex.     
F) Negative stained GST-BCL-10-MALT1 complex shows sphere shaped particles (110kx). 
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5 Discussion 
The API2-MALT1 fusion protein is frequently observed in MALT lymphoma and supports 
lymphoma development due to constitutive NF-κB activation (Akagi, 1999; Lucas, 2001). In 
particular, the BIR1 domain was expected to participate in this NF-κB activation mechanism 
by either supporting MALT1 oligomerization (Zhou, 2005) or by providing additional TRAF6 
binding sites. Regarding the oligomeric state of recombinant API2-MALT1, size-exclusion 
chromatography revealed similar to recombinant MALT1 mostly monomeric or by the 
paracaspase domain dimerized conformations, indicating no influence of the BIR1 domain on 
the general oligomeric state of API2-MALT1 under these conditions. The crystal structure of 
API2-MALT1 in complex with Z-VRPR-FMK shows no additional electron density for the 
BIR1 domain, expecting this domain to be flexible. Superposition of API2-MALT1 in 
complex with Z-VRPR-FMK and MALT1 bound to hex-LRSR-AOMK shows only minor 
differences (Fig. 5-1 A). Interestingly, biochemical analysis revealed that the BIR1 domain of 
API2-MALT1 enhances the protease activity compared to the equivalent MALT1 construct 
(Fig. 5-1 B). Thus, the BIR1 domain provides either a transient oligomerization interface and 
mediates closer proximity of the paracaspase domains or directly stimulates the protease 
activity by an unknown mechanism. In context of MALT1 oligomerization, CBM-complex 
assembly induces close proximity of the paracaspase domains by generating filamentous 
structures mediated by CARMA1 nuclei formation (Qiao, 2013). This mechanism was 
published during this thesis and is mostly in line with the by EM observed filamentous 
structures for the complex of BCL-10 and MALT1.   
 
Figure: 5-1: Crystal structure and activity assay of API2-MALT1. 
A) Superposition of API2-MALT1 structure (cyan and light cyan) with Z-VRPR-FMK (orange) 
bound in the active site and MALT1 structure (blue) bound to hex-LRSR-AOMK (yellow). 
B) Activity assay of MALT1-6xHis and API2-MALT1-6xHis (performed by Nagel D.). 
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Generally, MALT1 activation is divided into two pivotal steps. Although oligomerization is 
needed for activity, MALT1 can adopt an auto-inhibited dimeric state where the substrate 
binding loops, including the active site cysteine C464 harboring L2 loop, are in an inactive 
conformation (Fig. 5-2 A) (Wiesmann, 2012). Hence, a second activation step needs to take 
place to allow the formation of an active cysteine-histidine dyad and an enzymatic functional 
substrate recognition groove. Substrate binding induces conformational rearrangements of the 
paracaspase domain into a proteolytic proficient caspase (Wiesmann, 2012).  
 
Figure: 5-2: Superposition of MALT1 crystal structures. 
A) Superposition of dimeric MALT1 structure (gold) in complex with thioridazine (magenta) and 
ligand free MALT1 structure (grey) (Wiesmann, 2012)    
B) Superposition of MALT1 structure (blue) bound to hex-LRSR-AOMK (yellow) and ligand free 
MALT1 structure (grey) (Wiesmann, 2012)    
C) Superposition of dimeric MALT1 structure (gold) in complex with thioridazine (magenta) and 
MALT1 (blue) bound to hex-LRSR-AOMK (yellow) 
 
The comparison of hex-LRSR-AOMK bound and ligand free structures illustrates the 
conformational changes upon substrate binding (Fig. 5-2 B). Substrate recognition mediates 
reorganization of the MALT1 paracaspase domain dimer interface, mainly involving β-sheet 8 
and α-helix F. The active site of MALT1 is directly connected via the L4 loop to β-sheet 8. 
Mutation of R551 to glutamate, which is located in β-sheet 8, permits dimerization and 
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abolishes MALT1 protease activity (Wiesmann, 2012). In addition, K524 is located next to 
α-helix F and interacts with D330’ and E534’ of α-helix F’ from the opposing monomer. 
Moreover, E534 is stabilized by electrostatic interactions with K557, which is located in the 
loop emerging from β-sheet 8 and connects the paracaspase and Ig3 domain (Fig. 5-3 A). 
Mutation of K524 to glutamate permits dimerization (Fig. 5-3 B) and abolishes MALT1 
protease activity (Fig. 5-3 C). 
 
Figure: 5-3: MALT1 dimer interface presentation and analysis. 
A) Close up view of MALT1 bound to hex-LRSR-AOMK dimer interface with one monomer 
depicted in blue and the other monomer in cyan. Structural rearrangements are shown by 
superposition of one monomer (blue) with ligand free dimeric MALT1 (grey) (Wiesmann, 2012). 
The connection between the active site and the Ig3 domain is highlighted in orange and interacting 
residues are illustrated as sticks.  
B) Size-exclusion chromatogram of K524E mutant MALT1 after Z-VRPR-FMK incubation    
verifies dimer interface disruption, represented by only monomeric MALT1.  
C) The MALT1 activity assay (performed by Nagel D.) confirms dimerization to be essential for 
activation, since K524E mutant MALT1 shows similar to C464A mutant no protease activity. 
 
Besides dimer interface formation, substrate binding leads to reorganization of the active site 
loops L1-L4 implying conformational rearrangements of the whole MALT1 paracaspase 
domain (Fig. 5-4 A). Superposition of the ligand free and hex-LRSR-AOMK bound structure 
illustrates the movement of β-sheets 3A and 3B up to 3.8 Å and subsequent shift of α-helices 
C and D (Fig. 5-4 B). This concerted restructuring finally leads to the generation of a 
proteolytic proficient caspase and is directly connected via the L4 loop over β-sheet 8 and 
linking helix α1Ig3 to the conformation of the C-terminal Ig3 domain (Fig. 5-4 A). In 
summary, changes on the boundary of the caspase domain to the Ig3 domain are connected in 
several ways to the active site conformation.  
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Figure: 5-4: Structural rearrangements essential for MALT1 activation. 
A) Superposition of MALT1 bound to hex-LRSR-AOMK (blue) with ligand free MALT1 (grey) 
(Wiesmann, 2012) shows rearrangements of active site loops L2,L3 and L4. The connection between 
the active site and Ig3 domain connecting α-helix 1Ig3 of the hex-LRSR-AOMK bound MALT1 
structure is highlighted in orange  
B) Superposition of hex-LRSR-AOMK bound MALT1 (blue) and ligand free MALT1 (grey) 
(Wiesmann C, 2012) illustrates structural rearrangements of β-sheets 3A, 3B and α-helices C, D and 
1Ig3, essential for activation. 
C) Superposition of hex-LRSR-AOMK bound MALT1 (blue) and ligand free MALT1 (grey) 
(Wiesmann C, 2012) Ig3 domains. 
 
Inhibition of MALT1 proteolytic activity by phenothiazines prevents RelB cleavage, IL-2 
expression in activated T-cells and downregulates NF-κB gene transcription in ABC-DLBCL 
(Nagel, 2012). The crystal structure of MALT1 in complex with thioridazine reveals that the 
binding site of phenothiazine based compounds, is located on the opposite site relative to the 
paracaspase active site, in the interface between the paracaspase and the Ig3 domain 
connecting helix α1Ig3 (Fig. 5-2 A). A detailed analysis of the thioridazine binding site shows 
that the tricyclic ring system binds in a hydrophobic pocket composed of residues A394, F398 
and L401 in α-helix C and L346, V344 and V381 in β-sheets 1 and 2, respectively. In order to 
determine the correct orientation of the 2-methylthiophenothiazinering, a second dataset of 
the same crystal was collected at a wavelength of 1.9 Å. The calculation of an anomalous 
difference density map allowed exact positioning of the thioridazine sulfur atoms and 
guaranteed correct placement of the small molecule into the refined 2Fo-Fc electron density 
(Fig. 5-5 A). Superposition of MALT1 bound to hex-LRSR-AOMK with the thioridazine 
complex structure indicates that binding of the compound in between α-helices 1Ig3 and C 
prevents the above described second activation step into an enzymatic proficient protease 
(Fig. 5-5 B). The movement of α-helices C and D is probably hampered by the sandwiched 
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thioridazine. Therefore, β-sheets 3A and 3B cannot perform their pivotal shift (Fig. 5-5 B) 
and the important L2 loop cannot be rearranged. Upon inhibitor binding, the side chain of 
residue W580 on α-helix 1Ig3 is flipped out of the hydrophobic groove, resulting in 
displacement of α-helix 1Ig3 (Fig. 5-5 A). Probably triggered by rotation of this domain 
connecting α-helix, the entire Ig3 domain becomes more flexible and shifts at the tip of the 
domain up to 9.6 Å compared to hex-LRSR-AOMK bound MALT1 (Fig. 5-5 C) or ligand 
free MALT1 (Fig. 5-4 C). In addition, this significant shift results in a 4 Å displacement of 
K644 (Fig. 5-5 C), indicating additional impact on the TRAF6 interaction and probably 
prevents the activation supporting mono-ubiquitination on K644 (Pelzer, 2013).  
 
Figure: 5-5: Structural rearrangements induced by thioridazine binding. 
A) Detailed view of hydrophobic pocket with interacting residues shown as sticks. The violet mesh 
represents the refined 2Fo-Fc electron density map (contoured at 1σ) for the ligand, shown together 
with the yellow highlighted anomalous difference density map (contoured at 2.2σ). 
B) Superposition of hex-LRSR-AOMK bound MALT1 (blue) and thioridazine bound MALT1 (gold) 
illustrates structural changes essential for activation and clash of α-helix C with thioridazine.   
C) Superposition of hex-LRSR-AOMK bound MALT1 (blue) and thioridazine bound MALT1 (gold) 
Ig3 domains represents the significant shift of the entire Ig3domain. 
 
Biochemical and structural studies revealed that residues P2 and P3 are less selective and 
mainly coordinated by electrostatic interactions, while in position P4 leucine or phenylalanine 
are clearly preferred by the hydrophobic S4 pocket (Hachmann, 2012; Wiesmann, 2012) 
(Fig. 5-6 A). A detailed comparison of ligand free and hex-LRSR-AOMK bound MALT1 
structures offers insights in conformational rearrangements of the active site essential for 
activation. The position for P1 arginine is blocked by Q494 in the ligand free structure 
(Wiesmann, 2012) (Fig. 5-6 B). Moreover, the L2 loop containing active site cysteine C464 is 
shifted in contrast to the peptide inhibitor bound structure and is stabilized in this inactive 
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conformation by electrostatic interaction between K466 and Y434. The charge of the active 
site histidine H415 is responsible for the stabilization of the negative charge of the tetrahedral 
intermediate and is shielded by Y434. The backbone oxygen of P357 is responsible to keep 
H415 in place (Fig. 5-6 B). A closer inspection of the allosteric inhibited active site reveals 
that Y434 interacts with R465 in contrast to K466 in the ligand free structure and stabilizes 
the L2 loop in the inactive conformation differently (Fig. 5-6 C). 
 
Figure: 5-6: Superposition of active site conformations. 
A) Active site of hex-LRSR-AOMK (yellow) bound MALT1 (blue) with coordinating residues 
represented as sticks. 
B) Superposition of hex-LRSR-AOMK (blue) and ligand free MALT1 (grey) (Wiesmann, 2012). 
C) Superposition of thioridazine bound (gold) and ligand free MALT1 (grey) (Wiesmann, 2012). 
 
Inhibitor binding, results in the displacement of W580 on α-helix 1Ig3 from the hydrophobic 
groove into a solvent exposed environment (Fig. 5-7 A). This can be measured by 
fluorescence quenching, since solvent exposed aromatic residues emit less fluorescence after 
excitation at 285 nm. The inhibitory potential of the different phenothiazines or related small 
molecules is represented by fluorescence quenching determined association constants (KD). 
Since the association constants for monomeric and ligand free dimeric MALT1 are in a 
comparable range of approximately 20 μM, MALT1 is inhibited by phenothiazines or related 
small molecules independent of the oligomeric state (Fig. 5-7 B). Fluorescence intensity data 
were analyzed according to Stern-Volmer law (Eftink, 1981), pointing to a combination of 
dynamic and static fluorescence quenching effects (Fig. 5-7 C). In addition, the inhibitory 
potential of the different phenothiazines was determined by activity assay derived IC50-values. 
MALT1 activity represents cleavage of AMC molecules from the substrate Ac-LRSR-AMC 
by increasing fluorescence levels, due to the generation of a conjugated electron system by the 
cleaved AMC molecules. To verify the allosteric binding site, the main interaction between 
the N-methylpiperidine group of thioridazine and E397 (Fig. 5-5 A) was disrupted by 
mutating glutamate to alanine (E397A).  
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In order to prove the proposed inhibitor-binding mechanism in cells, from DLBCL patients 
derived HBL-1 cells, were transduced with either wt MALT1 or E397A mutant MALT1. 
Expression was induced by doxycycline prior to mepazine or thioridazine treatment. Analysis 
of the cell viability revealed that both compounds reduced the viability of cells transduced 
with wt MALT1 (Fig. 5-7 D), while HBL-1 cells transduced with the E397A mutant were 
mostly resistant to mepazine and thioridazine treatment (Fig. 5-7 E). Thus effects of the 
E397A mutation verify MALT1 as target of phenothiazines in vivo. 
 
Figure: 5-7: Fluorescence quenching assay and E397A mutant analysis. 
A) Close up view of W580 repositioning.     
B) Fluorescence quenching assay of monomeric and dimeric MALT1-6xHis. 
C) Stern-Volmer representation of fluorescence quenching assay. 
D) Cell viability assay for thioridazine and mepazine using wt MALT1 (performed by Nagel D.).     
E) Cell viability assay for thioridazine and mepazine with E397A MALT1 (performed by Nagel D.). 
F) Activity assay of GST-MALT1 and E397A mutant GST-MALT1 (performed by Nagel D.). 
 
Since the MALT1 cleavage assay of E397A mutant GST-MALT1 shows comparable activity 
to wt GST-MALT1 and increasing amounts of Z-VRPR-FMK peptide inhibitor result in an 
equivalent loss of activity, the E397A mutation has no influence on the general activity of 
MALT1 (Fig. 5-7 F). Analysis of E397A mutant MALT1 by the fluorescence quenching 
assay and by the MALT1 activity assay shows in comparison to wt MALT1 significant 
decreased inhibitory potentials, represented by 2.5 fold increased association constants and 
5 fold increased IC50-values for thioridazine (Fig. 5-8 A and B). In case of mepazine, 5 fold 
increased association constants and 60 fold increased IC50-values were determined for E397A 
mutant MALT1 compared to wt MALT1 (Fig. 5-8 E and F). Both assays confirm the binding 
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mechanism and show a good correlation between association constants and IC50-values. In 
addition, the significant increased association constants for E397A mutant MALT1 verify the 
fluorescence quenching assay. The crystal structure of thioridazine in complex with MALT1 
indicates preferential binding of (S)-thioridazine. Both assays show only minor differences 
between thioridazine enantiomers, illustrated by comparable association constants of 20 μM 
(Fig. 5-8 C) and IC50-values of 5 μM (Fig. 5-8 D). Interestingly, (S)-mepazine shows 
preferential binding, represented by a decreased association constant of 8.5 μM (Fig. 5-8 G) 
and by a 10 fold decreased IC50-value of 0.36 μM (Fig. 5-8 H) compared to (R)-mepazine. 
Identification of stereo-selective MALT1 inhibition by (S)-mepazine is the first step towards 
MALT1 optimized small molecule inhibitors and might be useful for further development. 
Therefore, these assays provide a valuable tool to assess the impact of chemical modifications 
of phenothiazines on the affinity to MALT1.  
 
 
Figure: 5-8: Fluorescence quenching assay and MALT1 activity assay. 
A) Fluorescence quenching assay of thioridazine with E397A mutant MALT1.  
B) MALT1 activity assay of thioridazine with E397A mutant MALT1 (performed by Nagel D.).   
C) Fluorescence quenching assay of thioridazine enantiomers. 
D) MALT1 activity assay of thioridazine enantiomers (performed by Nagel D.). 
E) Fluorescence quenching assay of mepazine with E397A mutant MALT1.   
F) MALT1 activity assay of mepazine with E397A mutant MALT1 (performed by Nagel D.). 
G) Fluorescence quenching assay of mepazine enantiomers. 
H) MALT1 activity assay of mepazine enantiomers (performed by Nagel D.). 
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Furthermore, the structure of MALT1 in complex with thioridazine explains the effect of 
different phenothiazine modifications on their inhibitory effectiveness (Nagel, 2012). On the 
one hand, the phenothiazine ring system represents an optimal size to fit in the hydrophobic 
pocket and only minor changes that enlarge the size or enhance the solubility are tolerated, 
like the 2-methylthio group in thioridazine (Fig. 5-9 A). In addition, the hydrogen bond of the 
N-methylpiperidine nitrogen of thioridazine to E397 seems to play a major role in MALT1 
recognition, as the phenothiazine backbone alone is only a very poor MALT1 inhibitor. All 
derivatives tested with a piperidyl ring system and nitrogen atom in a similar position to the 
piperidyl nitrogen atom showed an inhibitory effect in comparable range (Fig. 5-9 A and B). 
Modifications of the connecting alkyl chain by keto- or hydroxyl-groups (Fig. 5-9 C) result in 
up to 10 fold increased IC50-values (Nagel, 2012). Modifications like in 3,7-dinitro-10H-
phenothiazine (Fig. 5-9 D) result in a complete loss of inhibitory function (Nagel, 2012). In 
conclusion, both the methyl-piperidyl group and tri-cyclic ring system play equal important 
roles in drug recognition which is explicable with the presented complex structure.  
 
Figure: 5-9: Chemical structures of phenothiazines. 
A) Thioridazine.  
B) Mepazine. 
C) 1-(10H-phenothiazin-10-γlcarbonyl)-4-piperidinecarboxamide. 
D) 3,7-dinitro-10H-phenothiazine. 
 
Since the catalytic center of caspases shares a similar conformation (Ivachtchenko, 2009), 
inhibition by peptide like inhibitors is likely to affect several caspases. In contrast, non-
competitive, allosteric inhibition by small molecules is much more specific. Interestingly, 
thioridazine and mepazine have a clinical history as antipsychotic drugs. These molecules 
exert sedative effects by acting as a dopamine receptor antagonists in the brain and were used 
for psychiatric therapies (Seeman Lee, 1975). Recently, thioridazine attracted great attention 
for cancer therapy, due to a toxic effect on cancer stem cells (CSC) while having no effect on 
normal human pluripotent stem cells (hPSC) (Sachlos, 2012). Thioridazine affects CSC 
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survival by acting as dopamine receptor antagonist (Sachlos, 2012). Thus, thioridazine has the 
same target in psychiatric patients and CSC, leaving no option to improve effectiveness and 
selectivity of the anti-psychotic effect in the different diseases.  
In contrast to the role in CSC, inhibition of MALT1 by thioridazine prevents RelB cleavage, 
IL-2 expression of activated T-cells and downregulates NF-κB gene transcription in ABC-
DLBCL (Nagel, 2012). The transcription factor RelB negatively regulates NF-κB signaling 
by inhibiting RelA and c-Rel dependent transcription, which is usually abrogated by MALT1 
processing of RelB (Hailfinger, 2011). Interestingly, MALT1 inhibition by thioridazine and 
mepazine reduces ABC-DLBCL growth by an MALT1 proteolytic activity depending toxic 
effect specific for ABC-DLBCL and does not affect GCB-DLBCL, HBL1 or TM8 cells 
(Nagel, 2012). Identification of the thioridazine binding pocket on the target MALT1 opens 
new possibilities for medicinal chemistry to develop effective MALT1 inhibitors that do not 
affect the dopamine receptor. Since the antipsychotic effect is proposed to origin from 
(R)-thioridazine (Jortani, 1993), the in this thesis identified stereo-selective mechanism of 
inhibition is important for the development of more specific inhibitors with less side effects.  
Although, dopamine receptor antagonism might be tolerated in the treatment of high grade 
MALT1-dependent lymphoma, (S)-mepazine may be utilized as mild immunosuppressant that 
counteract overshooting immune responses in autoimmune diseases or allergic inflammation. 
Recently, (S)-mepazine was shown to have a significant effect on experimental autoimmune 
encephalomyelitis (EAE) (Mc Guire, 2014), which is the murine multiple sclerosis model and 
shows similar aberrant immune responses leading to tissue damage and demyelination in the 
CNS by auto-reactive T-cells.  
In particular, Th1 and Th17 cells play a major role in EAE (Jager, 2009) involving MALT1 
dependent processing of RelB. Stimulation of Th1 cells by IL-12 results in IFN-γ secretion to 
induce macrophages activation (Merrill, 1992) and depends on the NF-κB transcription 
factors c-Rel and RelB (Kontgen, 1995; Corn, 2005). Additionally, IL-23 driven GM-CSF 
secretion of Th17 cells is essential for EAE pathogenesis (El-Behi, 2011) and is either directly 
mediated by c-Rel activated transcription or indirectly by c-Rel dependent Rorɣt expression 
(Himes, 1996; Codarri, 2011). Moreover, c-Rel is involved in Treg cell differentiation by 
regulating FoxP3 expression (Zhang, 1999). RelA and RelB are essential for ɣδ-T-cell 
development to restrain the Treg response during EAE by an IL-23 dependent mechanism 
(Petermann, 2010; Powolny-Budnicka, 2011).  
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Similar to previously described NF-κB1 (p50), c-Rel and IKKβ deficient mice (Hilliard, 1999; 
Hilliard, 2002; Greve, 2007), MALT1 deficient mice are resistant to EAE due to an impaired 
auto-reactive T-cell immune response (Mc Guire, 2013). MALT1 deficiency results in a 
reduced amount of Th17 cells with normal expression levels of c-Rel and Rorɣt and lead to 
significant high levels of RelB in the nucleus and decreased expression of the Th17 effector 
cytokines IL-17 and GM-CSF (Brüstle, 2012). In contrast, Th1 differentiation and their ability 
for IFN-ɣ and GM-CSF expression, IL-4 secretion by Th2 cells or FoxP3 expression in Treg 
cells is not impaired in MALT1 deficient mice (Fig. 5-10) (Brüstle, 2012).  
Similar to MALT1 deficient mice, MALT1-C472A knock-in mice are resistant to EAE 
induction, but show in contrast to MALT1 deficient mice, increased expression of IFN-ɣ by 
Th1 cells and IL-4 by Th2 cells, resulting in lymphocyte expansion and accumulation of 
activated T-cells in lymph nodes (Gewies, 2014; Jaworski, 2014). MALT1 deficient and 
MALT1 C472A mutant mice show increased RelB levels, proposed to be responsible for 
inhibition of FoxP3 dependent Treg cell differentiation, since significantly reduced Treg cell 
populations were identified in both mice (Fig. 5-10). However, no altered FoxP3 mRNA 
levels could be detected and impaired Treg cell differentiation might depend on the MALT1 
protease activity in a cell-intrinsic manner, shifting immune tolerance towards autoimmunity. 
MALT1 C472A mice are prone for the development of autoimmune gastritis, proposed to 
result from the reduced Treg population (Jaworski, 2014).  
 
Figure: 5-10: MALT1 and T-cell immune response (adapted from Bertossi, 2014). 
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Since mepazine treatment in context of EAE results in decreased expression of IFN-ɣ by Th1 
cells and the Treg cell population is not affected (Mc Guire, 2014), effects of inhibition by 
phenothiazines are not comparable with MALT1 deficient or MALT1 C472A mutant mice. 
Moreover, the constitutive mode of inhibition by C472A mutation (Gewies, 2014) is not 
equivalent to the non-competitive, allosteric mode of inhibition by phenothiazines, thus 
therapeutic purposes are rather promising. Besides decreased expression of IFN-ɣ by Th1 
cells, mepazine treatment reduces expression levels of IL-13 by Th2 cells, IL-6 and IL-17 by 
Th17 cells, as well as TGF-β expression by Treg cells (Fig. 5-10) (Mc Guire, 2014). Thus, 
mepazine treatment leads to a general immune suppressive effect and rebalances immune 
overreaction (Bertossi, 2014), responsible for chronic inflammation and tissue damage. In 
particular, the combination of IL-6 with TGF-β supports the development of pathogenic Th17 
cells and is reduced by mepazine treatment (Veldhoen, 2006; Bettelli, 2008; Mc Guire, 2014). 
Influences of MALT1 inhibition by phenothiazines on DC and NK cell activation or 
developmental stages of B-cells and marginal zone B-cells, observed for the C472A mutant 
mice (Ruefli-Brasse, 2003; Ruland, 2003; Gewies, 2014; Jaworski, 2014) are not known, but 
could contribute to attenuation of EAE progression. JNK signaling is not affected in MALT1 
C472A mutant mice in contrast to MALT1 deficient mice, indicating that the scaffolding 
function of MALT1 is rather required than the proteolytic activity of MALT1 in this pathway 
(Ruland, 2003; Jaworski, 2014).  
In conclusion, inhibition of MALT1 by (S)-mepazine is very promising for the treatment of 
ABC-DLBCL or MS and the identification of phenothiazines as allosteric, non-competitive 
MALT1 inhibitors, as well as the possibility for stereo-selective MALT1 inhibition is of great 
significance for further studies.  
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6 Abbreviations 
ABC-DLBCL: Activated B-cell like diffuse large B-cell lymphoma  
ADCC:   Antibody-dependent cell-mediated cytotoxicity 
AMC:   7-amido-4-methylcoumarin 
Amp:    Ampicillin 
APCs:    Antigen-presenting cells 
API2   Inhibitor of apoptosis 2 
BAFF:   B-cell activating factor 
BCL-10:   B-cell lymphoma 10 
BCR:   B-cell receptor 
BIR:    Baculoviral IAP repeat 
Btk:    Bruton’s tyrosine kinase 
Cam:   Chloramphenicol 
CARD:  Caspase-recruitment domain 
CCR7:   C-C chemokine receptor type 7 
CD:   Cluster of differentiation 
cDNA:  Complementary deoxyribonucleic acid 
cFLIP:   Cellular FLICE-like inhibitory protein 
CLPs:   Common lymphoid progenitors 
CMPs:   Common myeloid progenitors  
CNS:   Central nervous system 
CSF:   Colony-stimulating factor 
CSR:   Class-switch recombination 
cTECs:  Cortical thymic epithelial cells 
CYLD:  Cylindromatosis 
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D:   Diversity 
DAG:   Diacylglycerol 
DAP12:  DNAX-activation protein 12 
DCs:   Dentric cells 
DD:   Death domain  
DLBCL:  Diffuse large B-cell lymphoma 
DN:   Double negative 
DP:   Double positive 
DTT:   Dithiothreitol 
EAE:   Encephalomyelitis 
EM:   Electron microscopy 
FDCs:   Follicular dendritic cells 
Fig.:   Figure 
FoxP3   Forkhead-box-protein P3 
GC:   Germinal centres () 
GCB:   Germinal center B-cell like 
GM:   Granulocyte macrophage 
GPCR:  G-protein coupled receptors 
GST:   Glutathione S-transferase 
HC:   Heavy-chain 
hex-LRSR-AOMK: Hexyl-leucine-arginine-serine-arginine-acyloxymethyl ketone 
HSCs:   Hematopoietic stem cells 
HTS:   High throughput screening 
IAP:   Inhibitors of apoptosis 
IC:   Inhibitory concentration 
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ICOSL:  Inducible T-cell co-stimulator ligand 
IFNγ:   Interferon gamma 
IgLs:   Immunoglobulin light chains 
IKK:   Inhibitor of NF-kB (IκB) kinase 
IL:   Interleukin 
ILCs:   Innate lymphoid cells 
IP3   Inositol triphosphate 
IPTG:   Isopropyl β-D-1-thiogalactopyranoside 
ITAM:   Immunoreceptor tyrosine-based activation motif 
IκBα    NF-κB inhibitor α 
J:   Joining  
Kan:   Kanamycin 
LB:   Lysogeny Broth 
LPS:   Lipopolysaccharides 
LTi:   Lymphoid tissue inducer cells 
MAGUK:  Membrane associated guanylate kinase 
MALT1  Mucosa associated lymphoid tissue lymphoma translocation protein 1 
MHC:   Major histocompatibility complex 
MOG:   Myelin oligodendrocyte glycoprotein 
MS:   Multiple sclerosis 
NaCl:   Sodium chloride 
NF-κB:  Nuclear factor kappa-light-chain-enhancer of activated B-cells 
NIK:   NF-κB inducing kinase 
Ni-NTA:  Nickel-nitrilotriacetic acid 
NK:   Natural killer 
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NKG2D:  Natural-killer group 2, member D 
NLS:   Nuclear localization signal 
PAMPs:  Pathogen-associated molecular patterns 
PCR:   Polymerase chain reaction 
PDK1:   Phosphoinositide-dependent kinase-1 
PEG:   Polyethylenglycole 
pH:   Pondus Hydrogenii 
PI-3-K:  Phosphatidyl-inositol-3-kinase 
PIP2:   Phosphatidyl-inositol-2-phosphat 
PIP3:   Phosphatidyl-inositol-3-phosphat 
PKC:   Protein kinase C 
PLCγ1:  Phospholipase-C-gamma-1 
PLCγ2:  Phospholipase-C-gamma-2 
PRRs:   Pattern-recognition receptors 
PT:   Pertussis toxin 
PTK:   Protein tyrosine kinase 
RA:   Rheumatoid arthritis 
Ring:   Really interesting new gene 
SCS:   Subcapsular sinus 
SD:   Shine-Dalgarno 
SDS-PAGE:  Sodium dodecyl sulfate polyacrylamide gel electrophoresis 
SeMet:  Seleno-methionine 
SH:   Src homology  
SHM:   Somatic hypermutation 
SP:   Single positive 
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TAK:   TGF-β activated kinase 1 
TCM:   Central memory T-cells 
TCR:   T-cell receptor 
TEM:   Effector memory T-cells 
TFH:   Follicular helper T-cells 
TGF-β:  Transforming growth factor-β 
Th:   T-helper 
TLRs:   Toll-like receptors 
TNF:   Tumor necrosis factor 
TNFR:   Tumor necrosis factor receptor 
TRAF6  TNF receptor associated factor 
Treg:   Regulatory T-cells 
TREM1:  Triggering receptor expressed on myeloid cells 1 
Tris:   Tris(hydroxymethyl)-aminomethane 
UBA:   Ubiquitin associated 
V:   Variable 
ZAP70:  Zeta-associated protein-70 
Z-VRPR-FMK: Carbobenzoxycarbonyl-val-arg-pro-arg-fluoromethylketone 
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